Journal of Movement Disorders

Brief communication

Evaluating the Validity and Reliability of the Korean Version of the Scales for Outcomes in Parkinson’s Disease–Cognition: Jinse Park, Eungseok Oh, Seong-Beom Koh, In-Uk Song, Tae-Beom Ahn, Sang Jin Kim, Sang-Myung Cheon, Yoon-Joong Kim, Jin Whan Cho, Hyeo-Il Ma, Mee Young Park, Jong Sam Baik, Phil Hyu Lee, Sun Ju Chung, Jong-Min Kim, Han-Joon Kim, Young-Hee Sung, Do Young Kwon, Jae-Hyeok Lee, Jee-Young Lee, Ji Seon Kim, Ji Young Yun, Hee Jin Kim, Jin Yong Hong, Mi-Jung Kim, Jinyoung Youn, Hui-Jun Yang, Won Tae Yoon, Sooyeoun You, Kyum-Yil Kwon, Su-Yun Lee, Younsoo Kim, Hee-Tae Kim, Joong-Seok Kim, Ji-Young Kim; J Mov Disord. 2024;17(3):328-332. Published online April 3, 2024; DOI: https://doi.org/10.14802/jmd.24061

1,370 View
70 Download

Abstract PDF Supplementary Material: Objective
The Scales for Outcomes in Parkinson’s Disease–Cognition (SCOPA-Cog) was developed to assess cognition in patients with Parkinson’s disease (PD). In this study, we aimed to evaluate the validity and reliability of the Korean version of the SCOPACog (K-SCOPA-Cog).
Methods
We enrolled 129 PD patients with movement disorders from 31 clinics in South Korea. The original version of the SCOPA-Cog was translated into Korean using the translation-retranslation method. The test–retest method with an intraclass correlation coefficient (ICC) and Cronbach’s alpha coefficient were used to assess reliability. Spearman’s rank correlation analysis with the Montreal Cognitive Assessment-Korean version (MOCA-K) and the Korean Mini-Mental State Examination (K-MMSE) were used to assess concurrent validity.
Results
The Cronbach’s alpha coefficient was 0.797, and the ICC was 0.887. Spearman’s rank correlation analysis revealed a significant correlation with the K-MMSE and MOCA-K scores (r = 0.546 and r = 0.683, respectively).
Conclusion
Our results demonstrate that the K-SCOPA-Cog has good reliability and validity.

Original Article

Association between Olfactory Deficit and Motor and Cognitive Function in Parkinson’s Disease: Han Soo Yoo, Seok Jong Chung, Yang Hyun Lee, Byoung Seok Ye, Young H. Sohn, Phil Hyu Lee; J Mov Disord. 2020;13(2):133-141. Published online April 6, 2020; DOI: https://doi.org/10.14802/jmd.19082

10,895 View
285 Download
24 Web of Science
24 Crossref

Objective
To investigate whether baseline olfactory dysfunction in Parkinson’s disease (PD) patients is associated with baseline and longitudinal motor and cognitive function.
Methods
We recruited 228 drug-naïve PD patients who were followed for a mean of 6 years. Patients underwent the Cross-Cultural Smell Identification Test (CCSIT), a neuropsychological test, and N-(3-[18F]fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl) nortropane positron emission tomography within 6 months of the baseline evaluation. Olfactory dysfunction was categorized as normosmia (CCSIT score ≥ 9), hyposmia (CCSIT score 5–8), and anosmia (CCSIT score ≤ 4). During the follow-up period, we investigated changes in the levodopa-equivalent dose (LED) and the occurrence of wearing-off, levodopa-induced dyskinesia, and dementia.
Results
Among the PD patients, 80.7% were hyposmic at the time of diagnosis, and 26.1% were anosmic. Baseline olfactory dysfunction was not associated with either initial parkinsonian motor symptoms or with the longitudinal LED increment and motor complications. Meanwhile, the anosmic group had lower baseline scores on the Korea version of the Boston Naming Test and Stroop color reading test than the normosmic and hyposmic groups. The anosmic group exhibited a higher rate of conversion to dementia than the normosmic [adjusted hazard ratio (HR) 3.99, 95% confidence interval (CI) 1.08–14.72] and hyposmic (adjusted HR 2.48, 95% CI 1.15–5.32) PD groups, regardless of baseline motor deficits and cognitive status.
Conclusion
Baseline olfactory dysfunction was not associated with motor deficits and complications, but it was associated with cognitive dysfunction and prognosis, suggesting that severe olfactory impairment may reflect early cortical involvement, probably in the frontotemporal region, and rapid spreading of Lewy body pathology.

Citations

Citations to this article as recorded by

Correlation of olfactory function factors with cardiac sympathetic denervation in Parkinson’s disease
Dong-Woo Ryu, Sang-Won Yoo, Ko-Eun Choi, Yoon-Sang Oh, Joong-Seok Kim
Journal of Neurology.2024; 271(3): 1397. CrossRef
Estimating motor progression trajectory pursuant to temporal dynamic status of cardiac denervation in Parkinson’s disease
Sang-Won Yoo, Dong-Woo Ryu, Yoon-Sang Oh, Seunggyun Ha, Chul Hyoung Lyoo, Yuna Kim, Ji-Yeon Yoo, Joong-Seok Kim
Journal of Neurology.2024; 271(4): 2019. CrossRef
Parkinson’s disease with hyposmia and dysautonomia: does it represent a distinct subtype?
So Hoon Yoon, Dae Hyuk You, Han Kyu Na, Sungwoo Kang, Kyoungwon Baik, Mincheol Park, Chul Hyoung Lyoo, Young H. Sohn, Phil Hyu Lee
Journal of Neurology.2024; 271(8): 5064. CrossRef
Unraveling olfactory subtypes in Parkinson’s disease and their effect on the natural history of the disease
Sang-Won Yoo, Dong-Woo Ryu, Yoonsang Oh, Seunggyun Ha, Chul Hyoung Lyoo, Joong-Seok Kim
Journal of Neurology.2024; 271(9): 6102. CrossRef
Determination of objective taste perception among Iranian medical sciences students during COVID‑19 pandemic in Yazd, Eastern Iran: a case-control pilot study
Samira Hajimaghsoodi, Elham Paydar, Fatemeh Owlia
BMC Infectious Diseases.2024;[Epub] CrossRef
Olfactory Dysfunction in Parkinson’s Disease, Its Functional and Neuroanatomical Correlates
Gabriel Torres-Pasillas, Donají Chi-Castañeda, Porfirio Carrillo-Castilla, Gerardo Marín, María Elena Hernández-Aguilar, Gonzalo Emiliano Aranda-Abreu, Jorge Manzo, Luis I. García
NeuroSci.2023; 4(2): 134. CrossRef
Impact of deep brain stimulation (DBS) on olfaction in Parkinson's disease: Clinical features and functional hypotheses
G. Brand, C. Bontempi, L. Jacquot
Revue Neurologique.2023; 179(9): 947. CrossRef
Sequential change in olfaction and (non) motor symptoms: the difference between anosmia and non-anosmia in Parkinson’s disease
Ting-Chun Fang, Yu-Shan Tsai, Ming-Hong Chang
Frontiers in Aging Neuroscience.2023;[Epub] CrossRef
Traumatic brain injury-induced inflammatory changes in the olfactory bulb disrupt neuronal networks leading to olfactory dysfunction
Xiang Liu, Zhuofan Lei, Dylan Gilhooly, Junyun He, Yun Li, Rodney M. Ritzel, Hui Li, Long-Jun Wu, Shaolin Liu, Junfang Wu
Brain, Behavior, and Immunity.2023; 114: 22. CrossRef
Serum Biomarkers of Olfactory Identification Deficits in Patients with Parkinson’s Disease
Fu-Jia Li, Yang-Dan-Yu Li, Xu Liu, Jie Zu, Wei Zhang, Qi-Hua Xiao, Xue-Bin Niu, Li Du, Chen-Chen Cui, Ru-Yu Zhang, Xiao-Qing He, Gui-Yun Cui, Chuan-Ying Xu, Dominic B. Fee
Acta Neurologica Scandinavica.2023; 2023: 1. CrossRef
UPSIT subitems may predict motor progression in Parkinson’s disease
Yu-Hsuan Lin, Ting-Chun Fang, Hsin-Bei Lei, Shih-Chi Chiu, Ming-Hong Chang, Yi-Jen Guo
Frontiers in Neurology.2023;[Epub] CrossRef
Olfactory dysfunction is associated with motor function only in tremor-dominant Parkinson’s disease
Fardin Nabizadeh, Kasra Pirahesh, Elham Khalili
Neurological Sciences.2022; 43(7): 4193. CrossRef
Novel diagnostic tools for identifying cognitive impairment using olfactory-stimulated functional near-infrared spectroscopy: patient-level, single-group, diagnostic trial
Jaewon Kim, Dong Keon Yon, Kyu Yeong Choi, Jang Jae Lee, Namwoo Kim, Kun Ho Lee, Jae Gwan Kim
Alzheimer's Research & Therapy.2022;[Epub] CrossRef
The Role of Olfactory System in the Etiogenesis of Parkinson’s Diseases: An Overview
Jiju Narayanan Avanipully, Dithu Thekkekkara, Sahyadri M, Vipan K. Parihar, Santhepete Nanjundaiah Manjula
Journal of Pharmacology and Pharmacotherapeutics.2022; 13(1): 31. CrossRef
International consensus statement on allergy and rhinology: Olfaction
Zara M. Patel, Eric H. Holbrook, Justin H. Turner, Nithin D. Adappa, Mark W. Albers, Aytug Altundag, Simone Appenzeller, Richard M. Costanzo, Ilona Croy, Greg E. Davis, Puya Dehgani‐Mobaraki, Richard L. Doty, Valerie B. Duffy, Bradley J. Goldstein, David
International Forum of Allergy & Rhinology.2022; 12(4): 327. CrossRef
Does Olfactory Dysfunction Correlate with Disease Progression in Parkinson’s Disease? A Systematic Review of the Current Literature
Tommaso Ercoli, Carla Masala, Gianluca Cadeddu, Marcello Mario Mascia, Gianni Orofino, Angelo Fabio Gigante, Paolo Solla, Giovanni Defazio, Lorenzo Rocchi
Brain Sciences.2022; 12(5): 513. CrossRef
Olfactory dysfunction and striatal dopamine transporter binding in motor subtypes of Parkinson’s disease
Fardin Nabizadeh, Fatemeh Sodeifian, Kasra Pirahesh
Neurological Sciences.2022; 43(8): 4745. CrossRef
Olfaction and Executive Cognitive Performance: A Systematic Review
Vasudeva Murthy Challakere Ramaswamy, Peter William Schofield
Frontiers in Psychology.2022;[Epub] CrossRef
Nasal and Parotid Blood Pool Activity Is Significantly Correlated with Metabolic Syndrome Components and Sleep Apnea
William T. Phillips, Nasser J. Issa, Shereef B. Elhalwagi, Hilda T. Draeger, Joyce G. Schwartz, Jonathan A. Gelfond
Metabolic Syndrome and Related Disorders.2022; 20(7): 395. CrossRef
Chronic neuropsychiatric sequelae of SARS‐CoV‐2: Protocol and methods from the Alzheimer's Association Global Consortium
Gabriel A. de Erausquin, Heather Snyder, Traolach S. Brugha, Sudha Seshadri, Maria Carrillo, Rajesh Sagar, Yueqin Huang, Charles Newton, Carmela Tartaglia, Charlotte Teunissen, Krister Håkanson, Rufus Akinyemi, Kameshwar Prasad, Giovanni D'Avossa, Gabriel
Alzheimer's & Dementia: Translational Research & Clinical Interventions.2022;[Epub] CrossRef
Machine learning-based prediction of cognitive outcomes in de novo Parkinson’s disease
Joshua Harvey, Rick A. Reijnders, Rachel Cavill, Annelien Duits, Sebastian Köhler, Lars Eijssen, Bart P. F. Rutten, Gemma Shireby, Ali Torkamani, Byron Creese, Albert F. G. Leentjens, Katie Lunnon, Ehsan Pishva
npj Parkinson's Disease.2022;[Epub] CrossRef
Impact of Subthalamic Deep Brain Stimulation on Hyposmia in Patients With Parkinson's Disease Is Influenced by Constipation and Dysbiosis of Microbiota
Chao Li, Ying Hou, Xu Wang, Yue-xuan Li, Feng Li, Chao Zhang, Wei-guo Li
Frontiers in Neurology.2021;[Epub] CrossRef
Hyposmia may predict development of freezing of gait in Parkinson’s disease
Jae Jung Lee, Jin Yong Hong, Jong Sam Baik
Journal of Neural Transmission.2021; 128(6): 763. CrossRef
Clinical and Dopamine Depletion Patterns in Hyposmia- and Dysautonomia-Dominant Parkinson’s Disease
Han Soo Yoo, Sangwon Lee, Seong Ho Jeong, Byoung Seok Ye, Young H. Sohn, Mijin Yun, Phil Hyu Lee
Journal of Parkinson's Disease.2021; 11(4): 1703. CrossRef

Review Article

Diagnostic Criteria for Dementia with Lewy Bodies: Updates and Future Directions: Masahito Yamada, Junji Komatsu, Keiko Nakamura, Kenji Sakai, Miharu Samuraki-Yokohama, Kenichi Nakajima, Mitsuhiro Yoshita; J Mov Disord. 2020;13(1):1-10. Published online November 8, 2019; DOI: https://doi.org/10.14802/jmd.19052

27,753 View
1,737 Download
51 Web of Science
56 Crossref

Abstract PDF

The aim of this article is to describe the 2017 revised consensus criteria for the clinical diagnosis of dementia with Lewy bodies (DLB) with future directions for the diagnostic criteria. The criteria for the clinical diagnosis of probable and possible DLB were first published as the first consensus report in 1996 and were revised in the third consensus report in 2005. After discussion at the International DLB Conference in Fort Lauderdale, Florida, USA, in 2015, the International DLB Consortium published the fourth consensus report including the revised consensus criteria in 2017. The 2017 revised criteria clearly distinguish between clinical features and diagnostic biomarkers. Significant new information about previously reported aspects of DLB has been incorporated, with increased diagnostic weighting given to rapid eye movement (REM) sleep behavior disorder (RBD) and iodine-123-metaiodobenzylguanidine (MIBG) myocardial scintigraphy. Future directions include the development of the criteria for early diagnosis (prodromal DLB) and the establishment of new biomarkers that directly indicate Lewy-related pathology, including α-synuclein imaging, biopsies of peripheral tissues (skin, etc.) for the demonstration of α-synuclein deposition, and biochemical markers (cerebrospinal fluid/blood), as well as the pathological evaluation of the sensitivity and specificity of the 2017 revised diagnostic criteria. In conclusion, the revised consensus criteria for the clinical diagnosis of DLB were reported with the incorporation of new information about DLB in 2017. Future directions include the development of the criteria for early diagnosis and the establishment of biomarkers directly indicative of Lewy-related pathology.

Citations

Citations to this article as recorded by

The Role of Electroconvulsive Therapy in the Treatment of Catatonia Associated With Lewy Body Dementia: A Case Report
Javeria Sahib Din, Thomas Boes, Ernesto Navarro Garcia, Hiba Al-Rubaye
Cureus.2024;[Epub] CrossRef
α-Synuclein pathology from the body to the brain: so many seeds so close to the central soil
Yunying Yang, Zhentao Zhang
Neural Regeneration Research.2024; 19(7): 1463. CrossRef
Suspecting Non-Alzheimer’s Pathologies and Mixed Pathologies: A Comparative Study Between Brain Metabolism and Tau Images
Vincent Malotaux, Lise Colmant, Lisa Quenon, Lara Huyghe, Thomas Gérard, Laurence Dricot, Adrian Ivanoiu, Renaud Lhommel, Bernard Hanseeuw
Journal of Alzheimer's Disease.2024; 97(1): 421. CrossRef
Supercomplex formation of mitochondrial respiratory chain complexes in leukocytes from patients with neurodegenerative diseases
Tsukasa Hara, Ryosuke Amagai, Ryuji Sakakibara, Ayako Okado-Matsumoto
The Journal of Biochemistry.2024; 175(3): 289. CrossRef
Latest advances in mechanisms of epileptic activity in Alzheimer’s disease and dementia with Lewy Bodies
Mariane Vicente, Kwaku Addo-Osafo, Keith Vossel
Frontiers in Neurology.2024;[Epub] CrossRef
The clinical diagnosis of Parkinson's disease
Renato P. Munhoz, Vitor Tumas, José Luiz Pedroso, Laura Silveira-Moriyama
Arquivos de Neuro-Psiquiatria.2024; 82(06): 001. CrossRef
Identification of Potentially Repurposable Drugs for Lewy Body Dementia Using a Network-Based Approach
Megha Manoj, Siddarth Sowmyanarayan, Arjun V. Kowshik, Jhinuk Chatterjee
Journal of Molecular Neuroscience.2024;[Epub] CrossRef
Altered structural and functional connectivity in Posterior Cortical Atrophy and Dementia with Lewy bodies
Neha Atulkumar Singh, Austin W. Goodrich, Jonathan Graff-Radford, Mary M. Machulda, Irene Sintini, Arenn F. Carlos, Carling G. Robinson, Robert I. Reid, Val J. Lowe, Clifford R. Jack, Ronald C. Petersen, Bradley F. Boeve, Keith A. Josephs, Kejal Kantarci,
NeuroImage.2024; 290: 120564. CrossRef
Clinicopathological correlation of cerebrospinal fluid alpha‐synuclein seed amplification assay in a behavioral neurology autopsy cohort
Niyatee Samudra, D. Luke Fischer, Steven Lenio, Argentina Lario Lago, Peter A. Ljubenkov, Julio C. Rojas, William W. Seeley, Salvatore Spina, Adam M. Staffaroni, Jonathan Tablante, Fattin Wekselman, Jennifer Lamoureux, Luis Concha‐Marambio, Lea T. Grinber
Alzheimer's & Dementia.2024; 20(5): 3334. CrossRef
New insight of exercise on dementia; combinatory effects of physical and cognitive exercise
Hyo-Jeong Cha, Jun Hong Park, Changwan Hong
Molecular & Cellular Toxicology.2024; 20(4): 767. CrossRef
Diagnostic Challenge of an Advanced Stage Dementia Case
Emin Taşkıran
European Journal of Geriatrics and Gerontology.2024; 6(1): 73. CrossRef
Dementia with Lewy bodies
Cheri M. Jrolf
JAAPA.2024;[Epub] CrossRef
Absolute quantitation of sympathetic nerve activity using [123I] metaiodobenzylguanidine SPECT-CT in neurology
Shintaro Saito, Kenichi Nakajima, Junji Komatsu, Takayuki Shibutani, Hiroshi Wakabayashi, Hiroshi Mori, Aki Takata, Kenjiro Ono, Seigo Kinuya
EJNMMI Reports.2024;[Epub] CrossRef
Sympathetic 123I-metaiodobenzylguanidine index for Lewy body disease: probability-based diagnosis and identifying patients exempt from late imaging
Kenichi Nakajima, Takeshi Matsumura, Junji Komatsu, Hiroshi Wakabayashi, Kenjiro Ono, Seigo Kinuya
Annals of Nuclear Medicine.2024; 38(10): 814. CrossRef
The usefulness of combined analysis using CIScore and VSRAD parameters for differentiating between dementia with Lewy body and Alzheimer’s disease
Gaku Honda, Shigeki Nagamachi, Mai Takahashi, Yukie Higuma, Tomonobu Tani, Kosuke Hida, Kengo Yoshimitsu, Koji Ogomori, Yoshio Tsuboi
Japanese Journal of Radiology.2024; 42(10): 1206. CrossRef
Biofluid Detection of Pathological α-Synuclein in the Prodromal Phase of Synucleinopathies
Annika Kluge, Alex Iranzo, Daniela Berg, Bastiaan R. Bloem, Lorraine V. Kalia, Ron B. Postuma
Journal of Parkinson's Disease.2024; 14(s2): S323. CrossRef
Multiple system atrophy: Diagnostic challenges and a proposed diagnostic algorithm
Deepmala Nandanwar, Daniel D. Truong
Clinical Parkinsonism & Related Disorders.2024; 11: 100271. CrossRef
Magnetic resonance imaging in the diagnosis of progressive supranuclear palsy: A case report and review of literature
Baraka Alphonce, Francisca Komanya, Mbelwa Bitesigilwe, John R. Meda, Azan Nyundo
Clinical Case Reports.2023;[Epub] CrossRef
Parkinson's disease fluid biomarkers for differential diagnosis of atypical parkinsonian syndromes
Jun Yang, Ayotimofe Idowu, Liana Rosenthal, Xiaobo Mao
Clinical and Translational Discovery.2023;[Epub] CrossRef
Neurofilament light chain is increased in the parahippocampal cortex and associates with pathological hallmarks in Parkinson’s disease dementia
Irene Frigerio, Max A. Laansma, Chen-Pei Lin, Emma J. M. Hermans, Maud M. A. Bouwman, John G. J. M. Bol, Yvon Galis-de Graaf, Dagmar H. Hepp, Annemieke J. M. Rozemuller, Frederik Barkhof, Wilma D. J. van de Berg, Laura E. Jonkman
Translational Neurodegeneration.2023;[Epub] CrossRef
Machine learning-based prediction of conversion coefficients for I-123 metaiodobenzylguanidine heart-to-mediastinum ratio
Koichi Okuda, Kenichi Nakajima, Chiemi Kitamura, Michael Ljungberg, Tetsuo Hosoya, Yumiko Kirihara, Mitsumasa Hashimoto
Journal of Nuclear Cardiology.2023; 30(4): 1630. CrossRef
Costs During the Last Five Years of Life for Patients with Clinical and Pathological Confirmed Diagnosis of Lewy Body Dementia and Alzheimer’s Disease
Carolyn W. Zhu, Yian Gu, Anton J. Kociolek, Kayri K. Fernandez, Stephanie Cosentino, Yaakov Stern
Journal of Alzheimer's Disease.2023; 92(2): 457. CrossRef
Early- and late-onset of isolated rapid eye movement sleep behavior disorder: A retrospective cohort study
Li Zhou, Bei Huang, Jing Wang, Steven WH. Chau, Joey WY. Chan, Jihui Zhang, Mandy WM. Yu, Jessie CC. Tsang, Shirley Xin Li, Vincent CT. Mok, Yun Kwok Wing, Yaping Liu
Sleep Medicine.2023;[Epub] CrossRef
Parkinson Disease Dementia Management: an Update of Current Evidence and Future Directions
Oliver Phillips, Debolina Ghosh, Hubert H. Fernandez
Current Treatment Options in Neurology.2023; 25(5): 93. CrossRef
Rapidly progressive dementia with severe insomnia: an unusual case of progressive supranuclear palsy mimicking dementia with Lewy bodies
Rae On Kim, Eun Ji Lee, Seong-Ik Kim, Sung-Hye Park, Kyum-Yil Kwon
Neurological Sciences.2023; 44(8): 2953. CrossRef
Significance of clinical symptoms and red flags in early differential diagnosis of Parkinson’s disease and atypical Parkinsonian syndromes
Nils Schröter, Thilo van Eimeren, Joseph Classen, Johannes Levin, Christoph Redecker, Martin Wolz, Lars Tönges
Journal of Neural Transmission.2023; 130(6): 839. CrossRef
Electroencephalography in young onset dementia
Casey W Brown, Huei-Yang Chen, Peter K Panegyres
BMC Neurology.2023;[Epub] CrossRef
Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers
Lucy L. Gibson, Carla Abdelnour, Joyce Chong, Clive Ballard, Dag Aarsland
Current Opinion in Neurology.2023;[Epub] CrossRef
Coexistence of Posterior Cortical Atrophy and Parkinson’s Disease
Eun-Byul Ko, Il-Joong Hwang, Jung-Woo Kim, Dar-Eun Jung, Ju-Suk Lee, Sang-Won Yoo, Joong-Seok Kim
Journal of the Korean Neurological Association.2023; 41(3): 216. CrossRef
Toward a new nosology of neurodegenerative diseases
Manuel Menéndez‐González
Alzheimer's & Dementia.2023; 19(8): 3731. CrossRef
Autonomic dysfunction in dementia with Lewy bodies: Focusing on cardiovascular and respiratory dysfunction
Katsuyoshi Mizukami
Psychiatry and Clinical Neurosciences Reports.2023;[Epub] CrossRef
Beyond Strains: Molecular Diversity in Alpha-Synuclein at the Center of Disease Heterogeneity
Marcelina J. Wojewska, Maria Otero-Jimenez, Jose Guijarro-Nuez, Javier Alegre-Abarrategui
International Journal of Molecular Sciences.2023; 24(17): 13199. CrossRef
Case Study 6: The Diagnostic Challenge of a 75-Year-Old Man Who Had, Then Didn’t Have, Then Did Have Alzheimer’s Disease
Sergio A. Ramírez-Salazar, Cassie MacRae, Mel B. Feany, Michael Miller, Hyun-Sik Yang, Mary-Ellen Meadows, Scott M. McGinnis, David Silbersweig, Seth A. Gale, Kirk R. Daffner
The Journal of Neuropsychiatry and Clinical Neurosciences.2023; 35(4): 325. CrossRef
Cardiac 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy in Parkinson’s Disease: A Comprehensive Review
Jamir Pitton Rissardo, Ana Letícia Fornari Caprara
Brain Sciences.2023; 13(10): 1471. CrossRef
A Unique Perspective on Lead Compounds for Dementia with the Lewy Body
Menaka Subramani, Amuthalakshmi Sivaperuman, Ramalakshmi Natarajan, Keerthana Dhinakaran
Medicinal Chemistry.2023; 19(10): 946. CrossRef
Three-Dimensional Heart Segmentation and Absolute Quantitation of Cardiac ¹²³I-metaiodobenzylguanidine Sympathetic Imaging Using SPECT/CT
Shintaro Saito, Kenichi Nakajima, Takayuki Shibutani, Hiroshi Wakabayashi, Hiroto Yoneyama, Takahiro Konishi, Hiroshi Mori, Aki Takata, Seigo Kinuya
Annals of Nuclear Cardiology.2023; 9(1): 61. CrossRef
Comparison of Taiwanese and European Calibration Factors for Heart-to-Mediastinum Ratio in Multicenter ¹²³I-mIBG Phantom Studies
Koichi Okuda, Kenichi Nakajima, Guang-Uei Hung, Hao-Ting Wu, Derk O. Verschure, Hein J. Verberne, Chiemi Kitamura
Annals of Nuclear Cardiology.2023; 9(1): 54. CrossRef
Clinical biomarkers for Lewy body diseases
Mai M. Abdelmoaty, Eugene Lu, Rana Kadry, Emma G. Foster, Shaurav Bhattarai, R. Lee Mosley, Howard E. Gendelman
Cell & Bioscience.2023;[Epub] CrossRef
Proteomic comparison between non‐purified cerebrospinal fluid and cerebrospinal fluid‐derived extracellular vesicles from patients with Alzheimer's, Parkinson's and Lewy body dementia
Yael Hirschberg, Natalia Valle‐Tamayo, Oriol Dols‐Icardo, Sebastiaan Engelborghs, Bart Buelens, Roosmarijn E. Vandenbroucke, Yannick Vermeiren, Kurt Boonen, Inge Mertens
Journal of Extracellular Vesicles.2023;[Epub] CrossRef
The connection between cerebral amyloid angiopathy and Alzheimer’s disease
Hans Rolf Jäger
European Radiology.2023; 34(4): 2171. CrossRef
Young-onset dementia with Lewy Bodies presenting with apathy and alexithymia
Stefania Kaninia, Rosaleen A. McCarthy, Zia Saad, George P Pengas
Neurocase.2023; 29(6): 191. CrossRef
Autonomic symptoms are predictive of dementia with Lewy bodies
Wenzheng Hu, Shuai Liu, Fei Wang, Han Zhu, Xiaoshan Du, Lingyun Ma, Jinghuan Gan, Hao Wu, Xiaodan Wang, Yong Ji
Parkinsonism & Related Disorders.2022; 95: 1. CrossRef
Delusion and Delirium in Neurodegenerative Disorders: An Overlooked Relationship?
Daniele Urso, Valentina Gnoni, Marco Filardi, Giancarlo Logroscino
Frontiers in Psychiatry.2022;[Epub] CrossRef
Clinical Trajectories at the End of Life in Autopsy-Confirmed Dementia Patients With Alzheimer Disease and Lewy Bodies Pathologies
Yian Gu, Anton Kociolek, Kayri K. Fernandez, Stephanie A. Cosentino, Carolyn Wei Zhu, Zhezhen Jin, James B. Leverenz, Yaakov B. Stern
Neurology.2022;[Epub] CrossRef
Diagnostic Performance for Differential Diagnosis of Atypical Parkinsonian Syndromes from Parkinson’s Disease Using Quantitative Indices of 18F-FP-CIT PET/CT
Miju Cheon, Seung Min Kim, Sang-Won Ha, Min Ju Kang, Hea-Eun Yang, Jang Yoo
Diagnostics.2022; 12(6): 1402. CrossRef
The promise of amplification assays for accurate early detection of α-synucleinopathies: A review
Regina Kurapova, Leonidas Chouliaras, John T. O'Brien
Experimental Gerontology.2022; 165: 111842. CrossRef
Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder
Annette Janzen, David Vadasz, Jan Booij, Markus Luster, Damiano Librizzi, Martin T. Henrich, Lars Timmermann, Mahboubeh Habibi, Elisabeth Sittig, Geert Mayer, Fanni Geibl, Wolfgang Oertel
Journal of Parkinson's Disease.2022; 12(6): 1921. CrossRef
A Systematic Review and Comparison of Neurocognitive Features of Late-Life Attention-Deficit/Hyperactivity Disorder and Dementia With Lewy Bodies
Jennifer L. Prentice, Morgan J. Schaeffer, Alexandra K. Wall, Brandy L. Callahan
Journal of Geriatric Psychiatry and Neurology.2021; 34(5): 466. CrossRef
Dementia with Lewy bodies in first-generation immigrants in a European memory clinic
Kurt Segers, Florence Benoit, Jean-Marie Meyts, Gérald Glibert, Sophie Levy, Murielle Surquin
Acta Neurologica Belgica.2021; 121(1): 219. CrossRef
The development of new method to differentiate between Dementia with Lewy bodies and Alzheimer’s disease by cerebral perfusion SPECT-comparison to CIScore
Gaku Honda, Shigeki Nagamachi, Masanari Nonokuma, Koichi Takano, Yasuo Kuwabara, Kengo Yoshimitsu, Hitoshi Iida, Koji Ogomori, Hiroaki Kawasaki, Yoshio Tsuboi
Japanese Journal of Radiology.2021; 39(2): 198. CrossRef
Impaired meningeal lymphatic drainage in patients with idiopathic Parkinson’s disease
Xue-Bing Ding, Xin-Xin Wang, Dan-Hao Xia, Han Liu, Hai-Yan Tian, Yu Fu, Yong-Kang Chen, Chi Qin, Jiu-Qi Wang, Zhi Xiang, Zhong-Xian Zhang, Qin-Chen Cao, Wei Wang, Jia-Yi Li, Erxi Wu, Bei-Sha Tang, Ming-Ming Ma, Jun-Fang Teng, Xue-Jing Wang
Nature Medicine.2021; 27(3): 411. CrossRef
Mechanisms of Neurodegeneration in Various Forms of Parkinsonism—Similarities and Differences
Dariusz Koziorowski, Monika Figura, Łukasz M. Milanowski, Stanisław Szlufik, Piotr Alster, Natalia Madetko, Andrzej Friedman
Cells.2021; 10(3): 656. CrossRef
Advances in computerized MRI‐based biomarkers in Alzheimer’s disease
Raymond Wong, Yishan Luo, Vincent Chung-tong Mok, Lin Shi
Brain Science Advances.2021; 7(1): 26. CrossRef
Convolutional neural network-based automatic heart segmentation and quantitation in 123I-metaiodobenzylguanidine SPECT imaging
Shintaro Saito, Kenichi Nakajima, Lars Edenbrandt, Olof Enqvist, Johannes Ulén, Seigo Kinuya
EJNMMI Research.2021;[Epub] CrossRef
A direct comparison of the 2005 and 2017 criteria for dementia with Lewy bodies
Kurt Segers, Florence Benoit, Jean‐Marie Meyts, Gerald Glibert, Murielle Surquin
Psychogeriatrics.2020; 20(5): 785. CrossRef
Calibrated scintigraphic imaging procedures improve quantitative assessment of the cardiac sympathetic nerve activity
Koichi Okuda, Kenichi Nakajima, Chiemi Kitamura, Yumiko Kirihara, Mitsumasa Hashimoto, Seigo Kinuya
Scientific Reports.2020;[Epub] CrossRef

Case Report

‘Hummingbird’ Sign in a Patient with Guam Parkinsonism-Dementia Complex: Tianrong Yeo, Louis CS Tan; J Mov Disord. 2017;10(3):145-148. Published online August 8, 2017; DOI: https://doi.org/10.14802/jmd.17025

7,287 View
139 Download
2 Web of Science
2 Crossref

Abstract PDF Supplementary Material

We present a case of a 71-year-old male Chamorro patient from Guam who presented with progressive supranuclear palsy (PSP)-Richardson’s syndrome. Considering his strong family history of parkinsonism and a PSP phenotype, he was clinically diagnosed with Guam parkinsonism-dementia complex (PDC). Magnetic resonance imaging (MRI) of the brain revealed prominent midbrain atrophy with preserved pontine volume, forming the ‘hummingbird’ sign, which has not been described before in Guam PDC. Molecular analysis of the chromosome 9 open reading frame 72 gene (C9orf72) showed only 6 GGGGCC repeats. We discuss the clinico-pathological similarities and differences between PSP and Guam PDC, and highlight the topography of neuropathological changes seen in Guam PDC to explain the appearance of the ‘hummingbird’ sign on MRI.

Citations

Citations to this article as recorded by

Discriminative pattern of reduced cerebral blood flow in Parkinson’s disease and Parkinsonism-Plus syndrome: an ASL-MRI study
Lina Cheng, Xiaoyan Wu, Ruomi Guo, Yuzhou Wang, Wensheng Wang, Peng He, Hanbo Lin, Jun Shen
BMC Medical Imaging.2020;[Epub] CrossRef
Tauopathy and Movement Disorders—Unveiling the Chameleons and Mimics
Jacky Ganguly, Mandar Jog
Frontiers in Neurology.2020;[Epub] CrossRef

Original Article

The MMSE and MoCA for Screening Cognitive Impairment in Less Educated Patients with Parkinson’s Disease: Ji In Kim, Mun Kyung Sunwoo, Young H. Sohn, Phil Hyu Lee, Jin Y. Hong; J Mov Disord. 2016;9(3):152-159. Published online September 21, 2016; DOI: https://doi.org/10.14802/jmd.16020

21,943 View
426 Download
42 Web of Science
40 Crossref

Abstract PDF

Objective
To explore whether the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) can be used to screen for dementia or mild cognitive impairment (MCI) in less educated patients with Parkinson’s disease (PD).
Methods
We reviewed the medical records of PD patients who had taken the Korean MMSE (K-MMSE), Korean MoCA (K-MoCA), and comprehensive neuropsychological tests. Predictive values of the K-MMSE and K-MoCA for dementia or MCI were analyzed in groups divided by educational level.
Results
The discriminative powers of the K-MMSE and K-MoCA were excellent [area under the curve (AUC) 0.86–0.97] for detecting dementia but not for detecting MCI (AUC 0.64–0.85). The optimal screening cutoff values of both tests increased with educational level for dementia (K-MMSE < 15 for illiterate, < 20 for 0.5–3 years of education, < 23 for 4–6 years, < 25 for 7–9 years, and < 26 for 10 years or more; K-MoCA < 7 for illiterate, < 13 for 0.5–3 years, < 16 for 4–6 years, < 19 for 7–9 years, < 20 for 10 years or more) and MCI (K-MMSE < 19 for illiterate, < 26 for 0.5–3 years, < 27 for 4–6 years, < 28 for 7–9 years, and < 29 for 10 years or more; K-MoCA < 13 for illiterate, < 21 for 0.5–3 years, < 23 for 4–6 years, < 25 for 7–9 years, < 26 for 10 years or more).
Conclusion
Both MMSE and MoCA can be used to screen for dementia in patients with PD, regardless of educational level; however, neither test is sufficient to discriminate MCI from normal cognition without additional information.

Citations

Citations to this article as recorded by

Association between executive and physical functions in people with Parkinson’s disease
Fatma Kübra Çekok, Turhan Kahraman, Arzu Genç, Gözde Duran, Berril Dönmez Çolakoğlu, Deniz Yerlikaya, Görsev Yener
Somatosensory & Motor Research.2024; 41(3): 142. CrossRef
Neurocognitive correlates of semantic memory navigation in Parkinson’s disease
Felipe Diego Toro-Hernández, Joaquín Migeot, Nicolás Marchant, Daniela Olivares, Franco Ferrante, Raúl González-Gómez, Cecilia González Campo, Sol Fittipaldi, Gonzalo M. Rojas-Costa, Sebastian Moguilner, Andrea Slachevsky, Pedro Chaná Cuevas, Agustín Ibáñ
npj Parkinson's Disease.2024;[Epub] CrossRef
Influence of cognitive reserve on cognitive and motor function in α-synucleinopathies: A systematic review and multilevel meta-analysis
Isaac Saywell, Lauren Foreman, Brittany Child, Alexander L. Phillips-Hughes, Lyndsey Collins-Praino, Irina Baetu
Neuroscience & Biobehavioral Reviews.2024; 161: 105672. CrossRef
Comparing Montreal Cognitive Assessment Performance in Parkinson’s Disease Patients: Age- and Education-Adjusted Cutoffs vs. Machine Learning
Kyeongmin Baek, Young Min Kim, Han Kyu Na, Junki Lee, Dong Ho Shin, Seok-Jae Heo, Seok Jong Chung, Kiyong Kim, Phil Hyu Lee, Young H. Sohn, Jeehee Yoon, Yun Joong Kim
Journal of Movement Disorders.2024; 17(2): 171. CrossRef
Comparison of mini nutritional assessment tool and geriatric nutrition risk index in predicting 12-year mortality among community-dwelling older persons
Tsai-Chung Li, Chia-Ing Li, Chiu-Shong Liu, Chih-Hsueh Lin, Shing-Yu Yang, Cheng-Chieh Lin
The Journal of Nutrition.2024;[Epub] CrossRef
Efficacy of personalized repetitive transcranial magnetic stimulation based on functional reserve to enhance ambulatory function in patients with Parkinson’s disease: study protocol for a randomized controlled trial
Seo Jung Yun, Ho Seok Lee, Dae Hyun Kim, Sun Im, Yeun Jie Yoo, Na Young Kim, Jungsoo Lee, Donghyeon Kim, Hae-Yeon Park, Mi-Jeong Yoon, Young Seok Kim, Won Hyuk Chang, Han Gil Seo
Trials.2024;[Epub] CrossRef
Cortical morphological alterations in cognitively normal Parkinson’s disease with severe hyposmia
Jing Li, Yan Xu, Xiaoming Liu, Fan Yang, Wenliang Fan
Brain Research.2024; 1844: 149150. CrossRef
Effect of Education on Discriminability of Montreal Cognitive Assessment Compared to Mini-Mental State Examination
Haeyoon Kim, Seonyeong Yang, Jaesel Park, Byeong Chae Kim, Kyung-Ho Yu, Yeonwook Kang
Dementia and Neurocognitive Disorders.2023; 22(2): 69. CrossRef
Altered connectivity in the cognitive control-related prefrontal cortex in Parkinson’s disease with rapid eye movement sleep behavior disorder
Jinjing Liu, Xiaoya Zou, Jinming Gu, Qian Yu, Zhaoying Dong, Hongzhou Zuo, Xiaocui Chen, Xinyi Du, Dezhi Zou, Yu Han, Juan Peng, Oumei Cheng
Brain Imaging and Behavior.2023; 17(6): 702. CrossRef
Resting-state electroencephalographic characteristics related to mild cognitive impairments
Seong-Eun Kim, Chanwoo Shin, Junyeop Yim, Kyoungwon Seo, Hokyoung Ryu, Hojin Choi, Jinseok Park, Byoung-Kyong Min
Frontiers in Psychiatry.2023;[Epub] CrossRef
Floor and ceiling effects on the Montreal Cognitive Assessment in patients with Parkinson’s disease in Brazil
Brenda Hanae Bentes Koshimoto, Pedro Renato de Paula Brandão, Vanderci Borges, Henrique Ballalai Ferraz, Artur Francisco Schumacher-Schuh, Carlos Roberto de Mello Rieder, Maira Rozenfeld Olchik, Ignacio Fernandez Mata, Vitor Tumas, Bruno Lopes Santos-Loba
Dementia & Neuropsychologia.2023;[Epub] CrossRef
Alerting network alteration in isolated rapid eye movement sleep behavior disorder patients with mild cognitive impairment
El Jeong, Kwang Su Cha, Hye-Rim Shin, Eun Young Kim, Jin-Sun Jun, Tae-Joon Kim, Jung-Ick Byun, Jung-Won Shin, Jun-Sang Sunwoo, Ki-Young Jung
Sleep Medicine.2022; 89: 10. CrossRef
What Do These Findings Tell Us? Comment on Tinella et al. Cognitive Efficiency and Fitness-to-Drive along the Lifespan: The Mediation Effect of Visuospatial Transformations. Brain Sci. 2021, 11, 1028
Robert E. Kelly, Anthony O. Ahmed, Matthew J. Hoptman
Brain Sciences.2022; 12(2): 165. CrossRef
Association Between Lipid Accumulation Product and Cognitive Function in Hypertensive Patients With Normal Weight: Insight From the China H-type Hypertension Registry Study
Yanyou Xie, Junpei Li, Guotao Yu, Xinlei Zhou, Wei Zhou, Lingjuan Zhu, Tao Wang, Xiao Huang, Huihui Bao, Xiaoshu Cheng
Frontiers in Neurology.2022;[Epub] CrossRef
Accuracy of Machine Learning Using the Montreal Cognitive Assessment for the Diagnosis of Cognitive Impairment in Parkinson’s Disease
Junbeom Jeon, Kiyong Kim, Kyeongmin Baek, Seok Jong Chung, Jeehee Yoon, Yun Joong Kim
Journal of Movement Disorders.2022; 15(2): 132. CrossRef
Annonaceae Consumption Worsens Disease Severity and Cognitive Deficits in Degenerative Parkinsonism
Laurent Cleret de Langavant, Emmanuel Roze, Aimée Petit, Benoit Tressières, Amin Gharbi‐Meliani, Hugo Chaumont, Patrick Pierre Michel, Anne‐Catherine Bachoud‐Lévi, Philippe Remy, Régine Edragas, Annie Lannuzel
Movement Disorders.2022; 37(12): 2355. CrossRef
Obesity marker trajectories and cognitive impairment in older adults: a 10-year follow-up in Taichung community health study for elders
Tsai-Chung Li, Chia-Ing Li, Chiu-Shong Liu, Chih-Hsueh Lin, Shing-Yu Yang, Cheng-Chieh Lin
BMC Psychiatry.2022;[Epub] CrossRef
The Six‐item Clock‐Drawing Scoring System: a rapid screening for cognitive impairment in Parkinson's disease
Praween Lolekha, Chanya Tangkanakul, Thanida Saengchatri, Pornlapat Kulkeartprasert
Psychogeriatrics.2021; 21(1): 24. CrossRef
Lack of association between proton pump inhibitor use and brain aging: a cross-sectional study
Nayeon Ahn, Stefan Frenzel, Katharina Wittfeld, Robin Bülow, Henry Völzke, Markus M. Lerch, Jean-Francois Chenot, Ulf Schminke, Michael Nolde, Ute Amann, Christa Meisinger, Jakob Linseisen, Sebastian E. Baumeister, Hans Jörgen Grabe, Ina-Maria Rückert-Ehe
European Journal of Clinical Pharmacology.2021; 77(7): 1039. CrossRef
A Comprehensive Meta-analysis on Short-term and Working Memory Dysfunction in Parkinson’s Disease
Ari Alex Ramos, Liana Machado
Neuropsychology Review.2021; 31(2): 288. CrossRef
The role of APOE in cognitive trajectories and motor decline in Parkinson’s disease
Sungyang Jo, Seon-Ok Kim, Kye Won Park, Seung Hyun Lee, Yun Su Hwang, Sun Ju Chung
Scientific Reports.2021;[Epub] CrossRef
Altered regional homogeneity and connectivity in cerebellum and visual-motor relevant cortex in Parkinson's disease with rapid eye movement sleep behavior disorder
Jinjing Liu, Guangying Shuai, Weidong Fang, Yingcheng Zhu, Huiyue Chen, Yuchan Wang, Qun Li, Yu Han, Dezhi Zou, Oumei Cheng
Sleep Medicine.2021; 82: 125. CrossRef
Extra-basal ganglia iron content and non-motor symptoms in drug-naïve, early Parkinson’s disease
Minkyeong Kim, Seulki Yoo, Doyeon Kim, Jin Whan Cho, Ji Sun Kim, Jong Hyun Ahn, Jun Kyu Mun, Inyoung Choi, Seung-Kyun Lee, Jinyoung Youn
Neurological Sciences.2021; 42(12): 5297. CrossRef
Regional Neural Activity Changes in Parkinson’s Disease-Associated Mild Cognitive Impairment and Cognitively Normal Patients
Yilan Xing, Shishun Fu, Meng Li, Xiaofen Ma, Mengchen Liu, Xintong Liu, Yan Huang, Guang Xu, Yonggang Jiao, Hong Wu, Guihua Jiang, Junzhang Tian
Neuropsychiatric Disease and Treatment.2021; Volume 17: 2697. CrossRef
Understanding fatigue in progressive supranuclear palsy
Jong Hyeon Ahn, Joomee Song, Dong Yeong Lee, Jinyoung Youn, Jin Whan Cho
Scientific Reports.2021;[Epub] CrossRef
Motor and Non-motor Symptoms Associated With Exercise Behavior in Parkinson's Disease Patients: Factors Differ Between Patients With and Without Postural Instability
Joomee Song, Jinyoung Youn, Young Eun Huh, Jun Kyu Mun, Jong Hyeon Ahn, Dongyeong Lee, Woo Young Shin, Jin Whan Cho
Frontiers in Neurology.2021;[Epub] CrossRef
Brainstem-Predominant Lewy-Related Pathology in a Patient with Parkinson’s Disease without Dementia
Ji-Hyun Choi, Sung-Hye Park, Sung Sup Park, Beomseok Jeon
Journal of Movement Disorders.2020; 13(1): 74. CrossRef
Parkinsonian Symptoms, Not Dyskinesia, Negatively Affect Active Life Participation of Dyskinetic Patients with Parkinson’s Disease
Etienne Goubault, Sarah Bogard, Pierre J. Blanchet, Erwan Bézard, Claude Vincent, Davide Martino, Justyna Sarna, Oury Monchi, Christian Duval
Tremor and Other Hyperkinetic Movements.2020;[Epub] CrossRef
Cortical thinning pattern according to differential nigrosome involvement in patients with Parkinson’s disease
Na-Young Shin, Bo-Hyun Kim, Eunkyeong Yun, Uicheul Yoon, Jong-Min Lee, Young Hee Sung, Eung Yeop Kim
NeuroImage: Clinical.2020; 28: 102382. CrossRef
Therapeutic Effect of Levodopa/Carbidopa/Entacapone on Sleep Disturbance in Patients with Parkinson’s Disease
Kye Won Park, Sungyang Jo, Seung Hyun Lee, Yun Su Hwang, Dagyo Lee, Ho-Sung Ryu, Sun Ju Chung
Journal of Movement Disorders.2020; 13(3): 205. CrossRef
The changes of exercise pattern and clinical symptoms in patients with Parkinson's disease in the era of COVID-19 pandemic
Joomee Song, Jong Hyeon Ahn, Inyoung Choi, Jun Kyu Mun, Jin Whan Cho, Jinyoung Youn
Parkinsonism & Related Disorders.2020; 80: 148. CrossRef
Pesticide exposure and cognitive decline in a rural South Korean population
Jae-Yeop Kim, Sung-jin Park, Sung-Kyung Kim, Chang-Soo Kim, Tae-Hei Kim, Seong-Ho Min, Sung-Soo Oh, Sang-Baek Koh, Stephen D. Ginsberg
PLOS ONE.2019; 14(3): e0213738. CrossRef
Cut-off points of the Portuguese version of the Montreal Cognitive Assessment for cognitive evaluation in Parkinson’s disease
Kelson James Almeida, Larissa Clementino Leite de Sá Carvalho, Tomásia Henrique Oliveira de Holanda Monteiro, Paulo Cesar de Jesus Gonçalves Júnior, Raimundo Nonato Campos-Sousa
Dementia & Neuropsychologia.2019; 13(2): 210. CrossRef
Effects of Acupuncture Therapy on MCI Patients Using Functional Near-Infrared Spectroscopy
Usman Ghafoor, Jun-Hwan Lee, Keum-Shik Hong, Sang-Soo Park, Jieun Kim, Ho-Ryong Yoo
Frontiers in Aging Neuroscience.2019;[Epub] CrossRef
Validation of the Conversion between the Mini-Mental State Examination and Montreal Cognitive assessment in Korean Patients with Parkinson’s Disease
Ryul Kim, Han-Joon Kim, Aryun Kim, Mi-Hee Jang, Hyun Jeong Kim, Beomseok Jeon
Journal of Movement Disorders.2018; 11(1): 30. CrossRef
Further evidence for a distinctive atypical degenerative parkinsonism in the Caribbean: A new cluster in the French West Indian Island of Martinique
Annie Lannuzel, Régine Edragas, Angéla Lackmy, Benoit Tressières, Véronique Pelonde, Mireille Edimo Nana Kaptué, Sylvie Mécharles, Alexis Demas, Billy François, Eavan McGovern, Marie Vidailhet, Bertrand Gaymard, Emmanuel Roze
Journal of the Neurological Sciences.2018; 388: 214. CrossRef
Follow-up of the manganese-exposed workers healthy cohort (MEWHC) and biobank management from 2011 to 2017 in China
Yanting Zhou, Xiaoting Ge, Yuefei Shen, Lian Qin, Yaoqiu Zhong, Chao Jiang, Cheng Su, Jinyu Huang, Suzhen Lin, Defu Li, Hong Cheng, Fu Wei, Songfeng Ou, Yunfeng Zou, Xiaobo Yang
BMC Public Health.2018;[Epub] CrossRef
The Prevalence of Cerebral Microbleeds in Non-Demented Parkinson's Disease Patients
Kyeong Joon Kim, Yun Jung Bae, Jong-Min Kim, Beom Joon Kim, Eung Seok Oh, Ji Young Yun, Ji Seon Kim, Han-Joon Kim
Journal of Korean Medical Science.2018;[Epub] CrossRef
Validation of MoCA-MMSE Conversion Scales in Korean Patients with Cognitive Impairments
Young Ik Jung, Eun Hye Jeong, Heejin Lee, Junghee Seo, Hyun-Jeong Yu, Jin Y. Hong, Mun Kyung Sunwoo
Dementia and Neurocognitive Disorders.2018; 17(4): 148. CrossRef
Validation of the Korean Version of the Scale for Outcomes in Parkinson’s Disease-Autonomic
Ji-Young Kim, In-Uk Song, Seong-Beom Koh, Tae-Beom Ahn, Sang Jin Kim, Sang-Myung Cheon, Jin Whan Cho, Yun Joong Kim, Hyeo-Il Ma, Mee-Young Park, Jong Sam Baik, Phil Hyu Lee, Sun Ju Chung, Jong-Min Kim, Han-Joon Kim, Young-Hee Sung, Do Young Kwon, Jae-Hyeo
Journal of Movement Disorders.2017; 10(1): 29. CrossRef

Case Report

Creutzfeldt-Jakob Disease in a Tertiary Care Hospital in Thailand: A Case Series and Review of the Literature: Praween Lolekha, Ahmed Rasheed, Chutanat Yotsarawat; J Mov Disord. 2015;8(3):136-140. Published online September 10, 2015; DOI: https://doi.org/10.14802/jmd.15014

19,022 View
85 Download
9 Web of Science
7 Crossref

Abstract PDF

Creutzfeldt-Jakob Disease (CJD) is an incurable and inevitably fatal neurodegenerative disorder. Although CJD has a worldwide distribution, there are no official statistics on CJD in Thailand. A diagnosis of CJD is suspected when a patient develops rapidly progressive dementia with myoclonus. However, CJD may be mistaken for a variety of illnesses because its initial presentation frequently consists of non-specific symptoms. Here, we examined cases of sporadic CJD (sCJD) from Thammasat University Hospital (a tertiary care hospital in Thailand) between January 1, 2012 and December 31, 2014. Three cases of probable and possible sCJD were collected. All cases presented with rapidly progressive cognitive dysfunction accompanied by spontaneous myoclonus. Classical electroencehalography changes and typical abnormal MRI features were observed. All of the cases died within a period of 8 months. None of the patients underwent brain biopsy. Our findings raise questions about the prevalence of CJD in Thailand, which needs further study.

Citations

Citations to this article as recorded by

Sporadic Creutzfeldt-Jakob disease: Brain MRI lesion features from 2 cases reports
Hoang Dinh Au, Nguyen Thu Lan, Nguyen Thai Binh, Le Tuan Linh, Ma Mai Hien, Nguyen Minh Duc
Radiology Case Reports.2024; 19(3): 939. CrossRef
A systemic analysis of Creutzfeldt Jakob disease cases in Asia
Urwah Rasheed, Sana Khan, Minahil Khalid, Aneeqa Noor, Saima Zafar
Prion.2024; 18(1): 11. CrossRef
Updated global epidemiology atlas of human prion diseases
Li-Ping Gao, Ting-Ting Tian, Kang Xiao, Cao Chen, Wei Zhou, Dong-Lin Liang, Run-Dong Cao, Qi Shi, Xiao-Ping Dong
Frontiers in Public Health.2024;[Epub] CrossRef
The importance of ongoing international surveillance for Creutzfeldt–Jakob disease
Neil Watson, Jean-Philippe Brandel, Alison Green, Peter Hermann, Anna Ladogana, Terri Lindsay, Janet Mackenzie, Maurizio Pocchiari, Colin Smith, Inga Zerr, Suvankar Pal
Nature Reviews Neurology.2021; 17(6): 362. CrossRef
Case series of Creutzfeldt-Jakob disease in a third-level hospital in Quito
Germaine Eleanor Torres Herrán, Andrés Damián Ortega Herrera, Braulio Martinez Burbano, Marcos Serrano-Dueñas, María Angélica Ortiz Yepez, Raúl Alberto Barrera Madera, Luis Alfredo Masabanda Campaña, Guillermo David Baño Jiménez, Denny Maritza Santos Salt
BMC Neurology.2018;[Epub] CrossRef
An Evaluation of Rapidly Progressive Dementia Culminating in a Diagnosis of Creutzfeldt–Jakob Disease
Parmvir Parmar, Curtis L. Cooper, Daniel Kobewka
Case Reports in Infectious Diseases.2018; 2018: 1. CrossRef
Diffusion-weighted MRI abnormalities antedate the onset of sporadic Creutzfeldt-Jakob disease
Keisuke Suzuki, Akiko Kawasaki, Takahide Nagashima, Koichi Hirata
Neurology.2016; 87(8): 843. CrossRef

Original Article

Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinson’s Disease Dementia: Yoon-Sang Oh, Joong-Seok Kim, Phil Hyu Lee; J Mov Disord. 2015;8(2):98-102. Published online May 31, 2015; DOI: https://doi.org/10.14802/jmd.15041

21,440 View
261 Download
27 Web of Science
30 Crossref

Abstract PDF

Objective A recent study showed that rivastigmine and memantin improved behavioral and psychiatric symptoms of dementia (BPSD) in Alzheimer’s dementia. Furthermore, according to recent guidelines presented by the Movement Disorder Society, rivastigmine is efficacious for the treatment of dementia in Parkinson’s disease (PD). We investigated the efficacy of rivastigmine for BPSD in patients with Parkinson’s disease dementia (PDD).
Methods Twenty-three patients in whom cognitive impairment occurred at least one year after a diagnosis of PD participated in this open-label trial. Cognitive, psychiatric, and motor symptoms were assessed before and after 24 weeks of treatment with rivastigmine using unstructured clinical assessments and rating scales including the Unified Parkinson’s Disease Rating Scale, Mini-Mental State Examination (MMSE), and the Neuropsychiatric Inventory.
Results Age (± standard deviation) was 74.7 ± 5.9 years, average duration of PD was 3.5 ± 3.7 years, Hoehn and Yahr scores were 2.2 ± 0.8, and baseline MMSE scores were 19.1 ± 4.2. Improvements in global mental symptoms and neuropsychiatric symptoms were significant; among them, hallucination, depression and appetite changes improved. Caregiver distress significantly decreased, including distress resulting from hallucinations, depression, apathy, and appetite changes.
Conclusions Although controlled trials are required, the findings suggest that rivastigmine is useful for control of several neuropsychiatric symptoms and beneficial for caregiver distress in patients with PDD.

Citations

Citations to this article as recorded by

The treatment of behavioural and psychological symptoms in dementia: pragmatic recommendations
Camille Mercier, Victoria Rollason, Mohamed Eshmawey, Aline Mendes, Giovanni B. Frisoni
Psychogeriatrics.2024; 24(4): 968. CrossRef
Pharmacological and Non-Pharmacological Treatments for Depression in Parkinson’s Disease: An Updated Review
Efthalia Angelopoulou, Evangelia Stanitsa, Claire Chrysanthi Karpodini, Anastasia Bougea, Dionysia Kontaxopoulou, Stella Fragkiadaki, Christos Koros, Vasiliki Epameinondas Georgakopoulou, George Fotakopoulos, Yiannis Koutedakis, Christina Piperi, Sokratis
Medicina.2023; 59(8): 1454. CrossRef
Treatment of Alzheimer’s disease
Aleksandra Klimkowicz-Mrowiec
Aktualności Neurologiczne.2023; 23(4): 145. CrossRef
Parkinsonism and dementia
Christos Koros, Leonidas Stefanis, Nikolaos Scarmeas
Journal of the Neurological Sciences.2022; 433: 120015. CrossRef
Current concepts in treating mild cognitive impairment in Parkinson's disease
Jay S. Schneider, Sandhya Kortagere
Neuropharmacology.2022; 203: 108880. CrossRef
Apathy in Parkinson’s Disease: Defining the Park Apathy Subtype
Ségolène De Waele, Patrick Cras, David Crosiers
Brain Sciences.2022; 12(7): 923. CrossRef
Acetylcholinesterase Inhibitors in the Treatment of Neurodegenerative Diseases and the Role of Acetylcholinesterase in their Pathogenesis
Łucja Justyna Walczak-Nowicka, Mariola Herbet
International Journal of Molecular Sciences.2021; 22(17): 9290. CrossRef
Diagnosis and treatment of old-onset Parkinson's disease
久大立花
Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics.2021; 58(3): 341. CrossRef
Neuropsychiatrische Störungen bei idiopathischem Parkinson-Syndrom
Mario Paulig
Nervenheilkunde.2021; 40(10): 752. CrossRef
Cannabis Dopaminergic Effects Induce Hallucinations in a Patient with Parkinson’s Disease
Katie Pizzolato, David Thacker, Nicole Del Toro-Pagán, Abeer Hanna, Jacques Turgeon, Adriana Matos, Nishita Amin, Veronique Michaud
Medicina.2021; 57(10): 1107. CrossRef
Effectiveness of clozapine, oxcarbazepine and rivastigmine combination in a bipolar disorder patient with initial cerebral atrophy
Paolo Morana, Federico Mucci, Stefano Baroni, Alessandra Della Vecchia, Armando Piccinni, Benedetto Morana, Donatella Marazziti
Clinical Case Reports.2020; 8(2): 254. CrossRef
Neuropsychiatric Disorders in Parkinson’s Disease: What Do We Know About the Role of Dopaminergic and Non-dopaminergic Systems?
Kathy Dujardin, Véronique Sgambato
Frontiers in Neuroscience.2020;[Epub] CrossRef
Depression Comorbid With Stroke, Traumatic Brain Injury, Parkinson’s Disease, and Multiple Sclerosis: Diagnosis and Treatment
Susan K. Conroy, Katherine B. Brownlowe, Thomas W. McAllister
Focus.2020; 18(2): 150. CrossRef
Identifying and responding to fatigue and apathy in Parkinson’s disease: a review of current practice
Claudia Lazcano-Ocampo, Yi Min Wan, Daniel J van Wamelen, Lucia Batzu, Iro Boura, Nataliya Titova, Valentina Leta, Mubasher Qamar, Pablo Martinez-Martin, K Ray Chaudhuri
Expert Review of Neurotherapeutics.2020; 20(5): 477. CrossRef
Diagnosis, treatment and management of apathy in Parkinson’s disease: a scoping review
Bria Mele, Shinia Van, Jayna Holroyd-Leduc, Zahinoor Ismail, Tamara Pringsheim, Zahra Goodarzi
BMJ Open.2020; 10(9): e037632. CrossRef
Pharmacological treatment of apathy in Lewy body disorders: A systematic review
Jennifer Liu, Christine A. Cooper, Daniel Weintraub, Nabila Dahodwala
Parkinsonism & Related Disorders.2019; 60: 14. CrossRef
Current treatment of behavioral and cognitive symptoms of Parkinson's disease
Irena Rektorova
Parkinsonism & Related Disorders.2019; 59: 65. CrossRef
Approach to the management of psychosis in Parkinson’s disease
Abhishek Lenka, Vasanthi Gomathinayagam, Laxman Bahroo
Annals of Movement Disorders.2019; 2(3): 83. CrossRef
Risk factors for non-motor symptoms in Parkinson's disease
Johan Marinus, Kangdi Zhu, Connie Marras, Dag Aarsland, Jacobus J van Hilten
The Lancet Neurology.2018; 17(6): 559. CrossRef
The efficacy of pharmacological approaches to therapy of the apathy syndrome in dementia disorders (the review)
A. S. Avedisova, A. B. Guekht, K. V. Zakharova, R. G. Akzhigitov
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova.2018; 118(4): 126. CrossRef
Rivastigmine as a Symptomatic Treatment for Apathy in Parkinson’s Dementia Complex: New Aspects for This Riddle
Rita Moretti, Paola Caruso, Matteo Dal Ben
Parkinson's Disease.2017; 2017: 1. CrossRef
Caregiver Burden in Parkinson Disease: A Critical Review of Recent Literature
Philip E. Mosley, Rebecca Moodie, Nadeeka Dissanayaka
Journal of Geriatric Psychiatry and Neurology.2017; 30(5): 235. CrossRef
Imaging the Etiology of Apathy, Anxiety, and Depression in Parkinson’s Disease: Implication for Treatment
Stephane Thobois, Stephane Prange, Véronique Sgambato-Faure, Léon Tremblay, Emmanuel Broussolle
Current Neurology and Neuroscience Reports.2017;[Epub] CrossRef
Parkinson’s Disease Psychosis: Presentation, Diagnosis and Management
Ruth B Schneider, Julia Iourinets, Irene H Richard
Neurodegenerative Disease Management.2017; 7(6): 365. CrossRef
Recent Advance in the Relationship between Excitatory Amino Acid Transporters and Parkinson’s Disease
Yunlong Zhang, Feng Tan, Pingyi Xu, Shaogang Qu
Neural Plasticity.2016; 2016: 1. CrossRef
Neuropsychiatric Issues in Parkinson’s Disease
Jeffrey W. Cooney, Mark Stacy
Current Neurology and Neuroscience Reports.2016;[Epub] CrossRef
Parkinson’s Disease Psychosis: Therapy Tips and the Importance of Communication Between Neurologists and Psychiatrists
Daniel Martinez-Ramirez, Michael S Okun, Michael S Jaffee
Neurodegenerative Disease Management.2016; 6(4): 319. CrossRef
Pimavanserin for the treatment of Parkinson’s disease psychosis
Ines Chendo, Joaquim J Ferreira
Expert Opinion on Pharmacotherapy.2016; 17(15): 2115. CrossRef
Apathy in Dementia: Systematic Review of Recent Evidence on Pharmacological Treatments
Fleur Harrison, Liesbeth Aerts, Henry Brodaty
Current Psychiatry Reports.2016;[Epub] CrossRef
Pharmacotherapies for Parkinson’s disease symptoms related to cholinergic degeneration
Santiago Perez-Lloret, María Cecilia Peralta, Francisco J. Barrantes
Expert Opinion on Pharmacotherapy.2016; 17(18): 2405. CrossRef

Review Article

¹²³I-Metaiodobenzylguanidine Myocardial Scintigraphy in Lewy Body-Related Disorders: A Literature Review: Eun Joo Chung, Sang Jin Kim; J Mov Disord. 2015;8(2):55-66. Published online May 31, 2015; DOI: https://doi.org/10.14802/jmd.15015

19,419 View
206 Download
48 Web of Science
46 Crossref

Abstract PDF

Lewy body-related disorders are characterized by the presence of Lewy bodies and Lewy neurites, which have abnormal aggregations of α-synuclein in the nigral and extranigral areas, including in the heart. 123I-metaiodobenzylguanidine (MIBG) scintigraphy is a well-known tool to evaluate cardiac sympathetic denervation in the Lewy body-related disorders. MIBG scintigraphy showed low uptake of MIBG in the Lewy body-related disorders, including Parkinson’s disease, dementia with Lewy bodies, pure autonomic failure and rapid eye movement sleep behavior disorder. This review summarizes previous results on the diagnostic applications of MIBG scintigraphy in Lewy body-related disorders.

Citations

Citations to this article as recorded by

Conventional magnetic resonance imaging key features for distinguishing pathologically confirmed corticobasal degeneration from its mimics: a retrospective analysis of the J-VAC study
Keita Sakurai, Aya M. Tokumaru, Mari Yoshida, Yuko Saito, Koichi Wakabayashi, Takashi Komori, Masato Hasegawa, Takeshi Ikeuchi, Yuichi Hayashi, Takayoshi Shimohata, Shigeo Murayama, Yasushi Iwasaki, Toshiki Uchihara, Motoko Sakai, Ichiro Yabe, Satoshi Tan
Neuroradiology.2024;[Epub] CrossRef
Blunted tachycardia and cardiac sympathetic denervation in isolated rapid eye movement sleep behavior disorder
Shota Saeda, Yukiyoshi Sumi, Koichi Fujiwara, Hiroshi Kadotani
BMC Neurology.2024;[Epub] CrossRef
Difference in gut microbial dysbiotic patterns between body-first and brain-first Parkinson's disease
Don Gueu Park, Woorim Kang, In-Ja Shin, Mauricio Chalita, Hyun-Seok Oh, Dong-Wook Hyun, Hyun Kim, Jongsik Chun, Young-Sil An, Eun Jeong Lee, Jung Han Yoon
Neurobiology of Disease.2024; 201: 106655. CrossRef
Sudden cardiac death in synucleinopathies
Keivan Javanshiri, Tove Drakenberg, Mattias Haglund, Elisabet Englund
Journal of Neuropathology & Experimental Neurology.2023; 82(3): 242. CrossRef
Optimal Protocol and Clinical Usefulness of 123I-MIBG Cardiac Scintigraphy for Differentiation of Parkinson’s Disease and Dementia with Lewy Body from Non-Parkinson’s Diseases
In Kook Chun
Nuclear Medicine and Molecular Imaging.2023; 57(3): 145. CrossRef
Cardiac 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy in Parkinson’s Disease: A Comprehensive Review
Jamir Pitton Rissardo, Ana Letícia Fornari Caprara
Brain Sciences.2023; 13(10): 1471. CrossRef
Differentiating Dementia with Lewy Bodies from Alzheimer's Disease Using the Fall Risk Evaluation Questionnaire
Masashi Tsujimoto, Keisuke Suzuki, Akinori Takeda, Naoki Saji, Takashi Sakurai, Yukihiko Washimi
Internal Medicine.2022; 61(11): 1687. CrossRef
Association of plasma α-synuclein with cardiac 123I-MIBG scintigraphy in early Parkinson’s disease
Don Gueu Park, Juhee Kang, Young-Sil An, Jaerak Chang, Jung Han Yoon
Neuroscience Letters.2022; 770: 136399. CrossRef
Clinical and imaging evidence of brain-first and body-first Parkinson's disease
Jacob Horsager, Karoline Knudsen, Michael Sommerauer
Neurobiology of Disease.2022; 164: 105626. CrossRef
Cardiac Alpha-Synuclein Is Present in Alpha-Synucleinopathies
Keivan Javanshiri, Tove Drakenberg, Mattias Haglund, Elisabet Englund
Journal of Parkinson's Disease.2022; 12(4): 1125. CrossRef
Cardiac 123I-MIBG normal uptake values are population-specific: Results from a cohort of controls over 60 years of age
G. Roberts, J.J. Lloyd, J.P.M. Kane, R. Durcan, S. Lawley, K. Howe, G.S. Petrides, J.T. O’Brien, A.J. Thomas
Journal of Nuclear Cardiology.2021; 28(4): 1692. CrossRef
Uniformity of cardiac 123I-MIBG uptake on SPECT images in older adults with normal cognition and patients with dementia
Gemma Roberts, Jim J. Lloyd, Elizabeth Jefferson, Joseph P.M. Kane, Rory Durcan, Sarah Lawley, George S. Petrides, Kim Howe, Iftikhar Haq, John T. O’Brien, Alan J. Thomas
Journal of Nuclear Cardiology.2021; 28(5): 2151. CrossRef
Myocardial Sympathetic Innervation Imaging with MIBG in Dementia with Lewy Bodies
Gagandeep Choudhary, Pradeep Bhambhvani
Journal of Nuclear Cardiology.2021; 28(5): 2164. CrossRef
Identification of BAG2 and Cathepsin D as Plasma Biomarkers for Parkinson’s Disease
Juhee Kang, Jae Whan Kim, Hansol Heo, Jihyun Lee, Kwan Yong Park, Jung Han Yoon, Jaerak Chang
Clinical and Translational Science.2021; 14(2): 606. CrossRef
Gastrointestinal Dysfunction in Parkinson’s Disease
Casper Skjærbæk, Karoline Knudsen, Jacob Horsager, Per Borghammer
Journal of Clinical Medicine.2021; 10(3): 493. CrossRef
Management of Hypertension and Blood Pressure Dysregulation in Patients with Parkinson’s Disease—a Systematic Review
Vasiliki Katsi, Ilias Papakonstantinou, Eirini Solomou, Alexios S. Antonopoulos, Charalambos Vlachopoulos, Konstantinos Tsioufis
Current Hypertension Reports.2021;[Epub] CrossRef
Lewy Body Dementias: A Coin with Two Sides?
Ángela Milán-Tomás, Marta Fernández-Matarrubia, María Cruz Rodríguez-Oroz
Behavioral Sciences.2021; 11(7): 94. CrossRef
Cardiac Autonomic Dysfunction Is Associated with Severity of REM Sleep without Atonia in Isolated REM Sleep Behavior Disorder
Sooyeoun You, Kyoung Sook Won, Keun Tae Kim, Hyang Woon Lee, Yong Won Cho
Journal of Clinical Medicine.2021; 10(22): 5414. CrossRef
A diagnostic strategy for Lewy body disease using DAT-SPECT, MIBG and Combined index
Fumi Sakamoto, Shinya Shiraishi, Koji Ogasawara, Noriko Tsuda, Masataka Nakagawa, Seiji Tomiguchi, Yasuyuki Yamashita
Annals of Nuclear Medicine.2020; 34(6): 415. CrossRef
Difference in cardiovascular response during orthostatic stress in Parkinson’s disease and multiple system atrophy
Tomohiko Nakamura, Masashi Suzuki, Masamichi Ueda, Yumiko Harada, Masaaki Hirayama, Masahisa Katsuno
Journal of Neural Transmission.2020; 127(10): 1377. CrossRef
Striatal dopamine activity and myocardial 123I-metaiodobenzylguanidine uptake in early Parkinson's disease
Yoon-Sang Oh, Joong-Seok Kim, Sang-Won Yoo, Eo-Jin Hwang, Chul Hyoung Lyoo, Kwang-Soo Lee
Parkinsonism & Related Disorders.2019; 63: 156. CrossRef
Initial Versus Follow-up Sequential Myocardial 123I-MIBG Scintigraphy to Discriminate Parkinson Disease From Atypical Parkinsonian Syndromes
Dong-Woo Ryu, Joong-Seok Kim, Jee-Eun Lee, Yoon-Sang Oh, Sang-Won Yoo, Ie Ryung Yoo, Kwang-Soo Lee
Clinical Nuclear Medicine.2019; 44(4): 282. CrossRef
Cardiac 123I-MIBG planar heart to mediastinum ratios depend on patient size; phantom studies suggest SPECT-CT could improve quantification
Gemma Roberts, Jim J Lloyd, George S Petrides, John T O’Brien, Alan J Thomas
Biomedical Physics & Engineering Express.2019; 6(1): 015011. CrossRef
Does sympathetic dysfunction occur before denervation in pure autonomic failure?
Ling Guo, Murray D. Esler, Carolina Sari, Sarah Phillips, Elisabeth A. Lambert, Nora E. Straznicky, Gavin W. Lambert, Susan J. Corcoran
Clinical Science.2018; 132(1): 1. CrossRef
Validation of Iodine-131-meta-iodobenzylguanidine cardiac scintigraphy in Parkinsonism: A preliminary study
Dan Xu, Wenjia Zhu, Li Huo, Shikun Zhu, Fang Li, Han Wang
Parkinsonism & Related Disorders.2018;[Epub] CrossRef
Extensive Delayed Brain Atrophy after Resuscitation in a Patient with Multiple System Atrophy
Sazuku Nisitani, Hirofumi Miyoshi, Yoji Katsuoka
Frontiers in Neurology.2018;[Epub] CrossRef
Optimizing Parkinson’s disease diagnosis: the role of a dual nuclear imaging algorithm
J. William Langston, Jesse C. Wiley, Michele Tagliati
npj Parkinson's Disease.2018;[Epub] CrossRef
Diagnostic biomarkers for Parkinson’s disease at a glance: where are we?
Ilaria Cova, Alberto Priori
Journal of Neural Transmission.2018; 125(10): 1417. CrossRef
Imaging the Autonomic Nervous System in Parkinson’s Disease
Karoline Knudsen, Per Borghammer
Current Neurology and Neuroscience Reports.2018;[Epub] CrossRef
A Review of Dementia with Lewy Bodies' Impact, Diagnostic Criteria and Treatment
Samuel D. Capouch, Martin R. Farlow, Jared R. Brosch
Neurology and Therapy.2018; 7(2): 249. CrossRef
The Utility of the Combined Use of ¹²³I-FP-CIT and ¹²³I-MIBG Myocardial Scintigraphy in Differentiating Parkinson’s Disease from Other Parkinsonian Syndromes
Eiji Matsusue, Yoshio Fujihara, Kenichiro Tanaka, Yuki Aozasa, Manabu Shimoda, Hiroyuki Nakayasu, Kazuhiko Nakamura, Toshihide Ogawa
Yonago Acta Medica.2018; 61(2): 117. CrossRef
Correction of collimator-dependent differences in the heart-to-mediastinum ratio in 123I-metaiodobenzylguanidine cardiac sympathetic imaging: Determination of conversion equations using point-source imaging
Yusuke Inoue, Yutaka Abe, Kei Kikuchi, Keiji Matsunaga, Ray Masuda, Kazutoshi Nishiyama
Journal of Nuclear Cardiology.2017; 24(5): 1725. CrossRef
Normal ‘heart’ in Parkinson's disease: is this a distinct clinical phenotype?
J.‐S. Kim, H.‐E. Park, I.‐S. Park, Y.‐S. Oh, D.‐W. Ryu, I.‐U. Song, Y.‐A. Jung, I. R. Yoo, H.‐S. Choi, P. H. Lee, K.‐S. Lee
European Journal of Neurology.2017; 24(2): 349. CrossRef
Diagnosis of dementia with Lewy bodies: can 123I-IMP and 123I-MIBG scintigraphy yield new core features?
Fumi Sakamoto, Shinya Shiraishi, Noriko Tsuda, Mamoru Hashimoto, Seiji Tomiguchi, Manabu Ikeda, Yasuyuki Yamashita
The British Journal of Radiology.2017;[Epub] CrossRef
Imaging Parkinson’s disease below the neck
Per Borghammer, Karoline Knudsen, Tatyana D. Fedorova, David J. Brooks
npj Parkinson's Disease.2017;[Epub] CrossRef
The utility of the combination of a SPECT study with [123I]-FP-CIT of dopamine transporters and [123I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes
Naoto Uyama, Hideki Otsuka, Takayoshi Shinya, Yoichi Otomi, Masafumi Harada, Wataru Sako, Yuishin Izumi, Ryuji Kaji, Yuya Watanabe, Satoru Takashi, Yamato Kunikane
Nuclear Medicine Communications.2017; 38(6): 487. CrossRef
Cardiac sympathetic denervation and dementia in de novo Parkinson's disease: A 7-year follow-up study
Mun Hee Choi, Jung Han Yoon, Suk Woo Yong
Journal of the Neurological Sciences.2017; 381: 291. CrossRef
Cardiovascular autonomic dysfunctions in elderly patients with essential tremor: comparison with healthy controls
Joong-Seok Kim, Yoon-Sang Oh, Hyung-Eun Park, Si-Hoon Lee, Jeong-Wook Park, In-Uk Song, Jae-Young An, Hun-Jun Park, Byung-Chul Son, Kwang-Soo Lee
Neurological Sciences.2016; 37(5): 711. CrossRef
Orthostatic hypotension and cardiac sympathetic denervation in Parkinson disease patients with REM sleep behavioral disorder
Joong-Seok Kim, Hyung-Eun Park, Yoon-Sang Oh, Si-Hoon Lee, Jeong-Wook Park, Byung-chul Son, Kwang-Soo Lee
Journal of the Neurological Sciences.2016; 362: 59. CrossRef
[123]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies
J. J. van der Zande, J. Booij, P. Scheltens, P. G. H. M. Raijmakers, A. W. Lemstra
European Journal of Nuclear Medicine and Molecular Imaging.2016; 43(6): 1060. CrossRef
Is dopamine transporter invariably impaired at the time of diagnosis in dementia with Lewy bodies?
Flavio Nobili, Dario Arnaldi, Silvia Morbelli
European Journal of Nuclear Medicine and Molecular Imaging.2016; 43(6): 1056. CrossRef
Imaging Systemic Dysfunction in Parkinson’s Disease
Per Borghammer, Karoline Knudsen, David J. Brooks
Current Neurology and Neuroscience Reports.2016;[Epub] CrossRef
123I‐2β‐carbomethoxy‐3β‐(4‐iodophenyl)‐N‐(3‐fluoropropyl) nortropane single photon emission computed tomography and 123I‐metaiodobenzylguanidine myocardial scintigraphy in differentiating dementia with lewy bodies from other dementias: A comparative study
Pietro Tiraboschi, Angelo Corso, Ugo Paolo Guerra, Flavio Nobili, Arnoldo Piccardo, Maria Lucia Calcagni, Duccio Volterrani, Diego Cecchin, Mauro Tettamanti, Luigi Antelmi, Simone Vidale, Leonardo Sacco, Maria Merello, Stefano Stefanini, Anna Micheli, Pao
Annals of Neurology.2016; 80(3): 368. CrossRef
On the Utility of MIBG SPECT/CT in Evaluating Cardiac Sympathetic Dysfunction in Lewy Body Diseases
Hayato Odagiri, Toru Baba, Yoshiyuki Nishio, Osamu Iizuka, Minoru Matsuda, Kentaro Inoue, Akio Kikuchi, Takafumi Hasegawa, Masashi Aoki, Atsushi Takeda, Yasuyuki Taki, Etsuro Mori, John Duda
PLOS ONE.2016; 11(4): e0152746. CrossRef
123I-MIBG myocardial scintigraphy and neurocirculatory abnormalities in patients with dementia with Lewy bodies and Alzheimer's disease
Joong-Seok Kim, Hyung-Eun Park, Yoon-Sang Oh, In-Uk Song, Dong-Won Yang, Jeong-Wook Park, Kwang-Soo Lee
Journal of the Neurological Sciences.2015; 357(1-2): 173. CrossRef
Orthostatic hypotension: managing a difficult problem
Pearl K Jones, Brett H Shaw, Satish R Raj
Expert Review of Cardiovascular Therapy.2015; 13(11): 1263. CrossRef

Original Article

Neuropsychiatric Symptoms in Parkinson’s Disease Dementia Are Associated with Increased Caregiver Burden: Yoon-Sang Oh, Ji E. Lee, Phil Hyu Lee, Joong-Seok Kim; J Mov Disord. 2015;8(1):26-32. Published online January 31, 2015; DOI: https://doi.org/10.14802/jmd.14019

21,563 View
122 Download
37 Web of Science
35 Crossref

Abstract PDF

Objective Neuropsychiatric symptoms are common in Parkinson’s disease dementia (PDD). Frequent and severe neuropsychiatric symptoms create high levels of distress for patients and caregivers, decreasing their quality of life. The aim of this study was to investigate neuropsychiatric symptoms that may contribute to increased caregiver burden in PDD patients.
Methods Forty-eight PDD patients were assessed using the 12-item Neuropsychiatric Inventory (NPI) to determine the frequency and severity of mental and behavioral problems. The Burden Interview and Caregiver Burden Inventory were used to evaluate caregiver burden.
Results All but one patient showed one or more neuropsychiatric symptoms. The three most frequent neuropsychiatric symptoms were apathy (70.8%) and anxiety (70.8%), followed by depression (68.7%). More severe neuropsychiatric symptoms were significantly correlated with increased caregiver burden. The domains of delusion, hallucination, agitation and aggression, anxiety, irritability and lability, and aberrant motor behavior were associated with caregiver stress. After controlling for age and other potential confounding variables, total NPI score was significantly associated with caregiver burden.
Conclusions The results of this study confirm that neuropsychiatric symptoms are frequent and severe in patients with PDD and are associated with increased caregiver distress. A detailed evaluation and management of neuropsychiatric symptoms in PDD patients appears necessary to improve patient quality of life and reduce caregiver burden.

Citations

Citations to this article as recorded by

Caregiver Burden of Patients With Huntington’s Disease in South Korea
Chan Young Lee, Chaewon Shin, Yun Su Hwang, Eungseok Oh, Manho Kim, Hyun Sook Kim, Sun Ju Chung, Young Hee Sung, Won Tae Yoon, Jin Whan Cho, Jae-Hyeok Lee, Han-Joon Kim, Hee Jin Chang, Beomseok Jeon, Kyung Ah Woo, Seong-Beom Koh, Kyum-Yil Kwon, Jangsup Mo
Journal of Movement Disorders.2024; 17(1): 30. CrossRef
Risk factors and intervention of caregiver burden in Parkinson’s disease: a systematic review and meta-analysis
Yan Zhao, Wenxiang Wu, Jianjun Wu, Bin Shen, Yanpei Cao, Yafang Xu
Quality of Life Research.2024; 33(7): 1753. CrossRef
Impact of advanced Parkinson’s disease on caregivers: an international real-world study
Pablo Martinez-Martin, Matej Skorvanek, Tove Henriksen, Susanna Lindvall, Josefa Domingos, Ali Alobaidi, Prasanna L. Kandukuri, Vivek S. Chaudhari, Apeksha B. Patel, Juan Carlos Parra, James Pike, Angelo Antonini
Journal of Neurology.2023; 270(4): 2162. CrossRef
Motor Complications and Treatment in Advanced Parkinson's Disease #456
Caroline E. Olvera, Jori E. Fleisher, Neha M. Kramer
Journal of Palliative Medicine.2023; 26(5): 730. CrossRef
A single centre prospective study of three device-assisted therapies for Parkinson’s disease
Hugo Morales-Briceño, Ainhi D. Ha, Han-Lin Chiang, Yicheng Tai, Florence C. F. Chang, David S. Tsui, Jane Griffith, Donna Galea, Samuel D. Kim, Belinda Cruse, Neil Mahant, Victor S. C. Fung
npj Parkinson's Disease.2023;[Epub] CrossRef
Unawareness of Apathy in Parkinson’s Disease: The Role of Executive Dysfunction on Symptom Recognition
Gianpaolo Maggi, Carmine Vitale, Alessia Delle Curti, Marianna Amboni, Gabriella Santangelo
Brain Sciences.2023; 13(6): 964. CrossRef
Caregiver Burden in Late-Stage Parkinsonism and Its Associations
Stefania Kalampokini, Adrianus L. A. J. Hommel, Stefan Lorenzl, Joaquim J. Ferreira, Wassilios G. Meissner, Per Odin, Bastiaan R. Bloem, Richard Dodel, Anette-Eleonore Schrag
Journal of Geriatric Psychiatry and Neurology.2022; 35(1): 110. CrossRef
Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson’s Disease: Real-World Evidence From G7 Countries
Angelo Antonini, Rajesh Pahwa, Per Odin, Tove Henriksen, Michael J. Soileau, Ramon Rodriguez-Cruz, Stuart H. Isaacson, Aristide Merola, Susanna Lindvall, Josefa Domingos, Ali Alobaidi, Yash J. Jalundhwala, Prasanna L. Kandukuri, Juan Carlos Parra, Pavnit
Neurology and Therapy.2022; 11(1): 303. CrossRef
Impact of Isolation During the COVID-19 Pandemic on the Patient Burden of Parkinson’s Disease: A PMD Alliance Survey
Neal Hermanowicz, Maria Cristina Ospina, Yasar Torres-Yaghi, Sherrie Gould, Kelly Papesh, Jason A Rivera, Susan Miller, Sarah Jones, Kelli Musick, Damian May
Neuropsychiatric Disease and Treatment.2022; Volume 18: 633. CrossRef
Exploring the experiences of living with Lewy body dementia: An integrative review
Allison Bentley, Tessa Morgan, Yakubu Salifu, Catherine Walshe
Journal of Advanced Nursing.2021; 77(12): 4632. CrossRef
Neuropsychiatric symptoms in Parkinson’s disease: association with caregiver distress and disease severity
Wan-Chen Tsai, Hui-Chen Lin, Chiung-Chih Chang, Wen-Neng Chang, Chih-Cheng Huang, Kuei-Yueh Cheng, Hung-Chen Wang, Wei-Che Lin, Sheng-Yuan Hsiao, Yun-Ru Lai, Cheng-Hsien Lu, Nai-Wen Tsai
International Psychogeriatrics.2020; 32(6): 733. CrossRef
Caregiver Burden, Quality of Life and Related Factors in Family Caregivers of Dementia Patients in Turkey
Zeliha Tulek, Dilek Baykal, Sumeyye Erturk, Basar Bilgic, Hasmet Hanagasi, I. Hakan Gurvit
Issues in Mental Health Nursing.2020; 41(8): 741. CrossRef
Identifying and responding to fatigue and apathy in Parkinson’s disease: a review of current practice
Claudia Lazcano-Ocampo, Yi Min Wan, Daniel J van Wamelen, Lucia Batzu, Iro Boura, Nataliya Titova, Valentina Leta, Mubasher Qamar, Pablo Martinez-Martin, K Ray Chaudhuri
Expert Review of Neurotherapeutics.2020; 20(5): 477. CrossRef
A systematic review of the association between individual behavioural and psychological symptoms in dementia and carer burden
Catriona George, Nuno Ferreira, Rosalind Evans, Victoria Honeyman
Working with Older People.2020; 24(3): 181. CrossRef
Impact of Supporting People with Advanced Parkinson’s Disease on Carer’s Quality of Life and Burden

Nicola Modugno, Angelo Antonini, Alessandro Tessitore, Pietro Marano, Francesco Ernesto Pontieri, Nicola Tambasco, Margherita Canesi, Giovanni Fabbrini, Mariachiara Sensi, Rocco Quatrale, Paolo Solla, Giovanni Defazio, Gabriella Melzi, Giuliana Gualberti,
Neuropsychiatric Disease and Treatment.2020; Volume 16: 2899. CrossRef
A Comparative Study of the Behavioral Profile of the Behavioral Variant of Frontotemporal Dementia and Parkinson’s Disease Dementia
Dinesh Saini, Adreesh Mukherjee, Arijit Roy, Atanu Biswas
Dementia and Geriatric Cognitive Disorders Extra.2020; 10(3): 182. CrossRef
The long‐term direct and indirect economic burden among Parkinson's disease caregivers in the United States
Pablo Martinez‐Martin, Dendy Macaulay, Yash J. Jalundhwala, Fan Mu, Erika Ohashi, Thomas Marshall, Kavita Sail
Movement Disorders.2019; 34(2): 236. CrossRef
The association between specific neuropsychiatric disturbances in people with Alzheimer's disease and dementia with Lewy bodies and carer distress
Toril Marie Terum, Ingelin Testad, Arvid Rongve, Dag Aarsland, Ellen Svendsboe, John Roger Andersen
International Journal of Geriatric Psychiatry.2019; 34(10): 1421. CrossRef
Trait Impulsivity Is Independent of Mild Cognitive Impairment in a Parkinson’s Disease Cohort
Ashani Jeyadevan, Megan C. Bakeberg, Michelle Byrnes, Jade Kenna, Soumya Ghosh, Rick Stell, Sue Walters, Tess Evans, Sarah McGregor, Malcolm Horne, Frank L. Mastaglia, Ryan S. Anderton
Parkinson's Disease.2019; 2019: 1. CrossRef
Caregiver burden and its related factors in advanced Parkinson’s disease: data from the PREDICT study
Alessandro Tessitore, Pietro Marano, Nicola Modugno, Francesco E. Pontieri, Nicola Tambasco, Margherita Canesi, Anna Latorre, Leonardo Lopiano, Mariachiara Sensi, Rocco Quatrale, Paolo Solla, Giovanni Defazio, Gabriella Melzi, Anna Maria Costanzo, Giulian
Journal of Neurology.2018; 265(5): 1124. CrossRef
Estudio observacional transversal de la sobrecarga en cuidadoras informales y los determinantes relacionados con la atención a las personas dependientes
Ana María Rodríguez-González, Eva Rodríguez-Míguez, Ana Duarte-Pérez, Eduardo Díaz-Sanisidro, Ángel Barbosa-Álvarez, Ana Clavería
Atención Primaria.2017; 49(3): 156. CrossRef
Cognitive impairment in Parkinson's disease: impact on quality of life of carers
RA Lawson, AJ Yarnall, F Johnston, GW Duncan, TK Khoo, D Collerton, JP Taylor, DJ Burn
International Journal of Geriatric Psychiatry.2017; 32(12): 1362. CrossRef
Rivastigmine as a Symptomatic Treatment for Apathy in Parkinson’s Dementia Complex: New Aspects for This Riddle
Rita Moretti, Paola Caruso, Matteo Dal Ben
Parkinson's Disease.2017; 2017: 1. CrossRef
The relationship of specific items on the Neuropsychiatric Inventory to caregiver burden in dementia: a systematic review
Toril Marie Terum, John Roger Andersen, Arvid Rongve, Dag Aarsland, Ellen J. Svendsboe, Ingelin Testad
International Journal of Geriatric Psychiatry.2017; 32(7): 703. CrossRef
Neuropsychiatric symptoms in Alzheimer’s disease: associations with caregiver burden and treatment outcomes
C.T. Chen, C.-C. Chang, W.-N. Chang, N.-W. Tsai, C.-C. Huang, Y.-T. Chang, H.-C. Wang, C.-T. Kung, Y.-J. Su, W.-C. Lin, B.-C. Cheng, C.-M. Su, S.-Y. Hsiao, C.-W. Hsu, C.-H. Lu
QJM: An International Journal of Medicine.2017; 110(9): 565. CrossRef
Hallucinations in Healthy Older Adults: An Overview of the Literature and Perspectives for Future Research
Johanna C. Badcock, Hedwige Dehon, Frank Larøi
Frontiers in Psychology.2017;[Epub] CrossRef
Dementia Caregiver Burden: a Research Update and Critical Analysis
Sheung-Tak Cheng
Current Psychiatry Reports.2017;[Epub] CrossRef
Patients and Their Caregivers’ Burdens for Parkinson’s Disease in Korea
Jong Sam Baik, Joong-Seok Kim, Seong-Beom Koh, Jin Whan Cho, Phil Hyu Lee, Hyeo-Il Ma, Yun Joong Kim, Tae-Beom Ahn, Sang Jin Kim, Yong Duk Kim, Seong-min Choi, Ho-Won Lee, Hee Tae Kim
Journal of Movement Disorders.2017; 10(3): 109. CrossRef
Prevalence and treatment pattern ofParkinson's disease dementia inKorea
Yoon‐Sang Oh, Joong‐Seok Kim, In‐Seok Park, Yong‐Soo Shim, In‐Uk Song, Jeong‐Wook Park, Phil‐Hyu Lee, Chul‐Hyung Lyoo, Tae‐Beom Ahn, Hyo‐Il Ma, Yong‐Duk Kim, Seong‐Beom Koh, Seung‐Jae Lee, Kwang‐Soo Lee
Geriatrics & Gerontology International.2016; 16(2): 230. CrossRef
Genetic architecture for human aggression: A study of gene–phenotype relationship in OMIM
Yanli Zhang‐James, Stephen V. Faraone
American Journal of Medical Genetics Part B: Neuropsychiatric Genetics.2016; 171(5): 641. CrossRef
The relationship between specific cognitive defects and burden of care in Parkinson's disease
Michael Zhong, Richard Peppard, Dennis Velakoulis, Andrew H. Evans
International Psychogeriatrics.2016; 28(2): 275. CrossRef
Effect of lumbo-peritoneal shunt surgery on neuropsychiatric symptoms in patients with idiopathic normal pressure hydrocephalus
Hideki Kanemoto, Hiroaki Kazui, Yukiko Suzuki, Syunsuke Sato, Haruhiko Kishima, Toshiki Yoshimine, Kenji Yoshiyama
Journal of the Neurological Sciences.2016; 361: 206. CrossRef
The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson’s disease
Stefan Hermanowicz, Neal Hermanowicz
Expert Review of Neurotherapeutics.2016; 16(6): 625. CrossRef
Neuropsychiatric symptoms in Serbian patients with Parkinson's disease
Mirjana Petrovic, Elka Stefanova, Ljubomir Ziropadja, Tanja Stojkovic, Vladimir S. Kostic
Journal of the Neurological Sciences.2016; 367: 342. CrossRef
Managing Cognition in Progressive Supranuclear Palsy
Timothy Rittman, Ian TS Coyle-Gilchrist, James B Rowe
Neurodegenerative Disease Management.2016; 6(6): 499. CrossRef

Review Article

New Perspective on Parkinsonism in Frontotemporal Lobar Degeneration: Hee Kyung Park, Sun J. Chung; J Mov Disord. 2013;6(1):1-8.; DOI: https://doi.org/10.14802/jmd.13001

25,239 View
247 Download
28 Crossref

Abstract PDF

Frontotemporal dementia (FTD) is the second most common type of presenile dementia. Three clinical prototypes have been defined; behavioral variant FTD, semantic dementia, and progressive nonfluent aphasia. Progressive supranuclear palsy, corticobasal degeneration, and motor neuron disease may possess clinical and pathological characteristics that overlap with FTD, and it is possible that they may all belong to the same clinicopathological spectrum. Frontotemporal lobar degeneration (FTLD) is a clinicopathological syndrome that encompasses a heterogenous group of neurodegenerative disorders. Owing to the advancement in the field of molecular genetics, diagnostic imaging, and pathology, FTLD has been the focus of great interest. Nevertheless, parkinsonism in FTLD has received relatively less attention. Parkinsonism is found in approximately 20–30% of patients in FTLD. Furthermore, parkinsonism can be seen in all FTLD subtypes, and some patients with familial and sporadic FTLD can present with prominent parkinsonism. Therefore, there is a need to understand parkinsonism in FTLD in order to obtain a better understanding of the disease. With regard to the clinical characteristics, the akinetic rigid type of parkinsonism has predominantly been described. Parkinsonism is frequently observed in familial FTD, more specifically, in FTD with parkinsonism linked to chromosome 17q (FTDP-17). The genes associated with parkinsonism are microtubule associated protein tau (MAPT), progranulin (GRN or PGRN), and chromosome 9 open reading frame 72 (C9ORF72) repeat expansion. The neural substrate of parkinsonism remains to be unveiled. Dopamine transporter (DAT) imaging revealed decreased uptake of DAT, and imaging findings indicated atrophic changes of the basal ganglia. Parkinsonism can be an important feature in FTLD and, therefore, increased attention is needed on the subject.

Citations

Citations to this article as recorded by

Unraveling the complex role of MAPT-containing H1 and H2 haplotypes in neurodegenerative diseases
Chiara Pedicone, Sarah A. Weitzman, Alan E. Renton, Alison M. Goate
Molecular Neurodegeneration.2024;[Epub] CrossRef
Genetic and clinical landscape of Chinese frontotemporal dementia: dominance of TBK1 and OPTN mutations
Haitian Nan, Yeon-Jeong Kim, Min Chu, Dan Li, Jieying Li, Deming Jiang, Yiming Wu, Toshihisa Ohtsuka, Liyong Wu
Alzheimer's Research & Therapy.2024;[Epub] CrossRef
Treatment of Acquired Deforming Hypertonia with Botulinum Toxin in Older Population: A Retrospective Study
Pablo Maldonado, Hugo Bessaguet, Cédric Chol, Pascal Giraux, Ludovic Lafaie, Ahmed Adham, Romain David, Thomas Celarier, Etienne Ojardias
Toxins.2024; 16(8): 365. CrossRef
Antidepressant medications in dementia: evidence and potential mechanisms of treatment-resistance
Harry Costello, Jonathan P. Roiser, Robert Howard
Psychological Medicine.2023; 53(3): 654. CrossRef
Movement disorders are linked to TDP-43 burden in the substantia nigra of FTLD-TDP brain donors
Luigi Fiondella, Priya Gami-Patel, Christian A. Blok, Annemieke J. M. Rozemuller, Jeroen J. M. Hoozemans, Yolande A. L. Pijnenburg, Marta Scarioni, Anke A. Dijkstra
Acta Neuropathologica Communications.2023;[Epub] CrossRef
Demencias degenerativas: ¿un dilema de síndromes o de enfermedades?
A. Robles Bayón
Neurología.2022; 37(6): 480. CrossRef
Degenerative dementias: a question of syndrome or disease?
A. Robles Bayón
Neurología (English Edition).2022; 37(6): 480. CrossRef
Deficient neurotransmitter systems and synaptic function in frontotemporal lobar degeneration—Insights into disease mechanisms and current therapeutic approaches
Nadine Huber, Sonja Korhonen, Dorit Hoffmann, Stina Leskelä, Hannah Rostalski, Anne M. Remes, Paavo Honkakoski, Eino Solje, Annakaisa Haapasalo
Molecular Psychiatry.2022; 27(3): 1300. CrossRef
Novel frameshift CTSF mutation causing kufs disease type B mimicking frontotemporal dementia-parkinsonism
Murat Gultekin, Zeynep Tufekcioglu, Recep Baydemir
Neurocase.2022; 28(1): 107. CrossRef
Dopamine Transporter Imaging for Frontotemporal Lobar Degeneration With Motor Neuron Disease
Ryota Kobayashi, Shinobu Kawakatsu, Makoto Ohba, Daichi Morioka, Masafumi Kanoto, Koichi Otani
Frontiers in Neuroscience.2022;[Epub] CrossRef
Investigational therapeutics for the treatment of progressive supranuclear palsy
David G Coughlin, Irene Litvan
Expert Opinion on Investigational Drugs.2022; 31(8): 813. CrossRef
Frequency and Longitudinal Course of Motor Signs in Genetic Frontotemporal Dementia
Sonja Schönecker, Francisco J. Martinez-Murcia, Boris-Stephan Rauchmann, Nicolai Franzmeier, Catharina Prix, Elisabeth Wlasich, Sandra V. Loosli, Katja Bochmann, Juan-Manuel Gorriz Saez, Robert Laforce, Simon Ducharme, Maria Carmela Tartaglia, Elizabeth F
Neurology.2022;[Epub] CrossRef
Multi-Modal Synergistic 99mTc-TRODAT-1 SPECT and MRI for Evaluation of the Efficacy of Hyperbaric Oxygen Therapy in CO-Induced Delayed Parkinsonian and Non-Parkinsonian Syndromes
Skye Hsin-Hsien Yeh, Chuang-Hsin Chiu, Hung-Wen Kao, Ching-Po Lin, Yu-Hus Lai, Wen-Sheng Huang
Antioxidants.2022; 11(11): 2289. CrossRef
Defective Lysosomal Lipid Catabolism as a Common Pathogenic Mechanism for Dementia
Jun Yup Lee, Oana C. Marian, Anthony S. Don
NeuroMolecular Medicine.2021; 23(1): 1. CrossRef
Different miRNA Profiles in Plasma Derived Small and Large Extracellular Vesicles from Patients with Neurodegenerative Diseases
Daisy Sproviero, Stella Gagliardi, Susanna Zucca, Maddalena Arigoni, Marta Giannini, Maria Garofalo, Martina Olivero, Michela Dell’Orco, Orietta Pansarasa, Stefano Bernuzzi, Micol Avenali, Matteo Cotta Ramusino, Luca Diamanti, Brigida Minafra, Giulia Peri
International Journal of Molecular Sciences.2021; 22(5): 2737. CrossRef
Parkin beyond Parkinson’s Disease—A Functional Meaning of Parkin Downregulation in TDP-43 Proteinopathies
Katarzyna Gaweda-Walerych, Emilia Jadwiga Sitek, Ewa Narożańska, Emanuele Buratti
Cells.2021; 10(12): 3389. CrossRef
Joint contractures and acquired deforming hypertonia in older people: Which determinants?
Patrick Dehail, Nathaly Gaudreault, Haodong Zhou, Véronique Cressot, Anne Martineau, Julie Kirouac-Laplante, Guy Trudel
Annals of Physical and Rehabilitation Medicine.2019; 62(6): 435. CrossRef
Review: Clinical, genetic and neuroimaging features of frontotemporal dementia
R. Convery, S. Mead, J. D. Rohrer
Neuropathology and Applied Neurobiology.2019; 45(1): 6. CrossRef
Granulin in Frontotemporal Lobar Degeneration: Molecular Mechanisms of the Disease
Zemfira N. Karamysheva, Elena B. Tikhonova, Andrey L. Karamyshev
Frontiers in Neuroscience.2019;[Epub] CrossRef
The Whole Exome Sequencing Clarifies the Genotype- Phenotype Correlations in Patients with Early-Onset Dementia
Yangqi Xu, Xiaoli Liu, Junyi Shen, Wotu Tian, Rong Fang, Binyin Li, Jianfang Ma, Li Cao, Shengdi Chen, Guanjun Li, Huidong Tang
Aging and disease.2018; 9(4): 696. CrossRef
Mouse models of frontotemporal dementia: A comparison of phenotypes with clinical symptomatology
Rebekah M. Ahmed, Muireann Irish, Janet van Eersel, Arne Ittner, Yazi D. Ke, Alexander Volkerling, Julia van der Hoven, Kimi Tanaka, Tim Karl, Michael Kassiou, Jillian J. Kril, Olivier Piguet, Jürgen Götz, Matthew C. Kiernan, Glenda M. Halliday, John R. H
Neuroscience & Biobehavioral Reviews.2017; 74: 126. CrossRef
Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases
Anne-Claire Dupont, Bérenger Largeau, Maria Santiago Ribeiro, Denis Guilloteau, Claire Tronel, Nicolas Arlicot
International Journal of Molecular Sciences.2017; 18(4): 785. CrossRef
Intrinsic functional connectivity alterations in progressive supranuclear palsy: Differential effects in frontal cortex, motor, and midbrain networks
Johannes Rosskopf, Martin Gorges, Hans‐Peter Müller, Dorothée Lulé, Ingo Uttner, Albert C. Ludolph, Elmar Pinkhardt, Freimut D. Juengling, Jan Kassubek
Movement Disorders.2017; 32(7): 1006. CrossRef
Phenotypic variability related to C9orf72 mutation in a large Sardinian kindred
Gianluca Floris, Giuseppe Borghero, Francesca Di Stefano, Rosanna Melis, Roberta Puddu, Laura Fadda, Maria R. Murru, Daniela Corongiu, Stefania Cuccu, Stefania Tranquilli, Antonino Cannas, Maria G. Marrosu, Adriano Chiò, Francesco Marrosu
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.2016; 17(3-4): 245. CrossRef
Clinical features ofTBK1carriers compared withC9orf72,GRNand non-mutation carriers in a Belgian cohort
Sara Van Mossevelde, Julie van der Zee, Ilse Gijselinck, Sebastiaan Engelborghs, Anne Sieben, Tim Van Langenhove, Jan De Bleecker, Jonathan Baets, Mathieu Vandenbulcke, Koen Van Laere, Sarah Ceyssens, Marleen Van den Broeck, Karin Peeters, Maria Mattheijs
Brain.2016; 139(2): 452. CrossRef
Characterization of Movement Disorder Phenomenology in Genetically Proven, Familial Frontotemporal Lobar Degeneration: A Systematic Review and Meta-Analysis
Carmen Gasca-Salas, Mario Masellis, Edwin Khoo, Binit B. Shah, David Fisman, Anthony E. Lang, Galit Kleiner-Fisman, Patrick Lewis
PLOS ONE.2016; 11(4): e0153852. CrossRef
The clinical spectrum of sporadic and familial forms of frontotemporal dementia
Ione O. C. Woollacott, Jonathan D. Rohrer
Journal of Neurochemistry.2016; 138(S1): 6. CrossRef
Genetics of Progressive Supranuclear Palsy
Sun Young Im, Young Eun Kim, Yun Joong Kim
Journal of Movement Disorders.2015; 8(3): 122. CrossRef

Case Reports

A Case of Multiple System Atrophy-Cerebellar Type Preceded by Dementia: Eun Hye Jang, Joo Kyung Lee, Hyun Jung Jang, Mi-Jung Kim, Sun Ju Chung; J Mov Disord. 2012;5(2):48-52.; DOI: https://doi.org/10.14802/jmd.12011

17,270 View
95 Download
4 Crossref

Abstract PDF

Multiple system atrophy (MSA) is a sporadic, adult-onset disease characterized by progressive degeneration of nervous systems including cerebellar, pyramidal, extrapyramidal, and autonomic system. Although a few recent studies reported that cognitive impairments could occur in patients with MSA, prominent dementia with progressive decline is not a typical clinical manifestation of MSA. In particular, dementia with MSA-cerebellar type is very rare. We have experienced a patient with 2-year history of severe cognitive impairment, who was finally diagnosed as MSA-cerebellar type.

Citations

Citations to this article as recorded by

Delivering the diagnosis of multiple system atrophy: a multicenter survey on Japanese neurologists’ perspectives
Miki Yoshitake, Atsuhiko Sugiyama, Takayoshi Shimohata, Nobuyuki Araki, Masahide Suzuki, Kazumoto Shibuya, Kengo Nagashima, Nobutaka Hattori, Satoshi Kuwabara
BMC Neurology.2024;[Epub] CrossRef
Mitochondrial dysfunction and altered ribostasis in hippocampal neurons with cytoplasmic inclusions of multiple system atrophy
Norihisa Maeda, Hiroyuki Honda, Satoshi O. Suzuki, Naoki Fujii, Jun‐ichi Kira, Toru Iwaki
Neuropathology.2018; 38(4): 361. CrossRef
Mechanisms and prevention of sudden death in multiple system atrophy
Takayoshi Shimohata, Naotaka Aizawa, Hideaki Nakayama, Hiroshige Taniguchi, Yasuyoshi Ohshima, Hitoshi Okumura, Tetsuya Takahashi, Akio Yokoseki, Makoto Inoue, Masatoyo Nishizawa
Parkinsonism & Related Disorders.2016;[Epub] CrossRef
Fragile X-associated tremor/ataxia syndrome: phenotypic comparisons with other movement disorders
Erin E. Robertson, Deborah A. Hall, Andrew R. McAsey, Joan A. O’Keefe
The Clinical Neuropsychologist.2016; 30(6): 849. CrossRef

Levodopa-Induced Facial Dystonia in a Case of Progressive Supranuclear Palsy: Eun Joo Chung, Sang Jin Kim; J Mov Disord. 2012;5(1):28-32.; DOI: https://doi.org/10.14802/jmd.12008

17,461 View
70 Download
4 Crossref

Abstract PDF

Progressive supranuclear palsy (PSP) is frequently misdiagnosed as other Parkinsonism because of clinical heterogeneity of PSP. We present here a case of a 67-year-old male patient with frontotemporal dementia-like cognitive impairment including language difficulties and abnormal behaviors. He showed severe facial dystonia after the levodopa treatment. Herein, we describe an unusual case of a patient presenting with PSP which, we believe could contribute to our knowledge about atypical leveodopa-induced facial dystonia in PSP.

Citations

Citations to this article as recorded by

Use of botulinum toxin in the management of dystonia in Parkinson’s disease
Charenya Anandan, Joseph Jankovic
Frontiers in Neuroscience.2024;[Epub] CrossRef
Lower Cranial Dystonia with Inflated Cheeks: A Case of Dystonic Respiratory Failure
Takashi Suzuki, Takao Makifuchi, Nobuyoshi Fukuhara
Internal Medicine.2023; 62(11): 1671. CrossRef
Dystonia in atypical parkinsonian disorders
Luca Marsili, Matteo Bologna, Maja Kojovic, Alfredo Berardelli, Alberto J. Espay, Carlo Colosimo
Parkinsonism & Related Disorders.2019; 66: 25. CrossRef
A Review of Treatment Options for Progressive Supranuclear Palsy
Maria Stamelou, Günter Höglinger
CNS Drugs.2016; 30(7): 629. CrossRef

Review Articles

Clinicopathological Correlates of Lewy Body Disease: Fundamental Issues: Tae-Beom Ahn; J Mov Disord. 2010;3(1):11-14.; DOI: https://doi.org/10.14802/jmd.10003

11,035 View
63 Download
3 Crossref

Abstract PDF

Lewy body pathology (LBP) is the pathological hallmark of Lewy body diseases, such as Parkinson’s disease and Lewy body dementia. Recent studies have shed new light on the role of LBP, the interactions of LBP with concomitant pathologies, and the propagation of LBP from the olfactory bulb and enteric nervous system to the central nervous system. The intrinsic difficulty with identifying clinicopathological correlates could be overcome by improving our understanding of the pathological evolution of LBP.

Citations

Citations to this article as recorded by

Demencias degenerativas: ¿un dilema de síndromes o de enfermedades?
A. Robles Bayón
Neurología.2022; 37(6): 480. CrossRef
Degenerative dementias: a question of syndrome or disease?
A. Robles Bayón
Neurología (English Edition).2022; 37(6): 480. CrossRef
Advances in NURR1-Regulated Neuroinflammation Associated with Parkinson’s Disease
Murad Al-Nusaif, Yushan Lin, Tianbai Li, Cheng Cheng, Weidong Le
International Journal of Molecular Sciences.2022; 23(24): 16184. CrossRef

Comparing Cerebral White Matter Lesion Burdens between Parkinson’s Disease with and without Dementia: Sun-Ah Choi, Virgilio Gerald H. Evidente, John N Caviness; J Mov Disord. 2010;3(1):6-10.; DOI: https://doi.org/10.14802/jmd.10002

19,392 View
72 Download
3 Crossref

Abstract PDF

Cerebral white matter lesions (CWMLs) have been suggested to be associated with an increased risk of dementia, disability, and death. CWMLs are more common in individuals with Alzheimer’s disease (AD) than in normal elderly individuals of comparable age. Only a few studies have been done to determine whether CWMLs may influence cognitive decline in Parkinson’s disease (PD). Fully developed PD with concurrent AD was reported to likely cause impaired cognition in spite of accumulating evidence suggesting that PD with dementia (PDD) is more closely associated with Lewy body (LB) pathology. Currently, contradictory data on the neuropathology of dementia in PD require further prospective clinicopathological studies in larger cohorts to elucidate the impact of AD and α-synuclein (SCNA) pathologies on the cognitive status in these disorders. Previous reports did not suggest CWMLs to be associated with an increased risk of PDD. After adjusting for age at death, age at onset of PD, and duration of PD, our recent study investigating CWMLs in PDD via autopsy has shown a positive correlation between the burden of CWMLs and PDD. The frequent co-existence of both LB and AD lesions suggests that both pathologies independently or synergistically contribute to both movement disorders and cognitive impairment. The individual and cumulative burden of CWMLs, LB lesions, and AD lesions may synergistically contribute to cognitive decline in LB disorders such as PDD.

Citations

Citations to this article as recorded by

Cx43 Mediates Resistance against MPP+-Induced Apoptosis in SH-SY5Y Neuroblastoma Cells via Modulating the Mitochondrial Apoptosis Pathway
In-Su Kim, Palanivel Ganesan, Dong-Kug Choi
International Journal of Molecular Sciences.2016; 17(11): 1819. CrossRef
Gray and White Matter Contributions to Cognitive Frontostriatal Deficits in Non-Demented Parkinson's Disease
Catherine C. Price, Jared Tanner, Peter T. Nguyen, Nadine A. Schwab, Sandra Mitchell, Elizabeth Slonena, Babette Brumback, Michael S. Okun, Thomas H. Mareci, Dawn Bowers, Stephen D Ginsberg
PLOS ONE.2016; 11(1): e0147332. CrossRef
White Matter Hypoperfusion and Damage in Dementia: Post‐Mortem Assessment
Seth Love, J Scott Miners
Brain Pathology.2015; 25(1): 99. CrossRef

Original Article

Mild Cognitive Impairment in Parkinson’s Disease: Jae Woo Kim, Hee Young Jo, Min Jeong Park, Sang-Myung Cheon; J Mov Disord. 2008;1(1):19-25.; DOI: https://doi.org/10.14802/jmd.08004

9,882 View
94 Download
8 Web of Science
6 Crossref

Abstract PDF

Background

To determine the frequency of mild cognitive impairment (MCI) of Parkinson’s disease (PD, PDMCI) and its subtypes among non-demented PD patients, and to identify the influence of the age and presenting symptom on the development of PDMCI.

Methods:

A total 141 non-demented PD patients underwent a comprehensive neuropsychological assessment including attention, language, visuospatial, memory and frontal functions. PDMCI was defined by neuropsychological testing and was classified into five subtypes. Patients were divided into two groups (tremor vs. akinetic-rigid type) for presenting symptom and three groups according to the age. Neuropsychological performance of patients was compared with normative data.

Results:

Almost half (49.6%) of non-demented PD patients had impairment in at least one domain and can be considered as having PDMCI. Executive type of PDMCI was the most frequent and amnestic, visuospatial, linguistic and attention types followed in the order of frequency. The population of PDMCI was increasing as the age of disease onset was higher. Whereas the frequency of executive and amnestic types of PDMCI was comparable in younger group, executive type was the most frequent in older group. The patients with tremor dominant type performed worse on tests, particularly on attention test.

Conclusions:

MCI was common even in the early stage of PD and the subtype was diverse. Unlike MCI developing Alzheimer’s disease later, executive type of PDMCI was the most common. Age was an important risk factor for development of MCI in PD. The concept of MCI should be introduced in PD.

Citations

Citations to this article as recorded by

Orthostatic Hypotension and Cognitive Impairment in <i>De Novo</i> Patients with Parkinson’s Disease
Hyo-Jin Bae, Jun-Ho Lim, Sang-Myung Cheon
Journal of Movement Disorders.2014; 7(2): 102. CrossRef
Correlated regions of cerebral blood flow with clinical parameters in Parkinson’s disease; comparison using ‘Anatomy’ and ‘Talairach Daemon’ software
Hyun Jin Yoon, Sang Myung Cheon, Young Jin Jeong, Do-Young Kang
Annals of Nuclear Medicine.2012; 26(2): 164. CrossRef
Correlation between neuropsychological tests and hypoperfusion in MCI patients: anatomical labeling using xjView and Talairach Daemon Software
Hyun Jin Yoon, Kyung Won Park, Young Jin Jeong, Do-Young Kang
Annals of Nuclear Medicine.2012; 26(8): 656. CrossRef
Significant correlation between cerebral hypoperfusion and neuropsychological assessment scores of patients with mild cognitive impairment
Hyun Jin Yoon, Kyung Won Park, Young Jin Jeong, Do-Young Kang
Nuclear Medicine Communications.2012; 33(8): 848. CrossRef
Utility and Limitations of Addenbrooke’s Cognitive Examination-Revised for Detecting Mild Cognitive Impairment in Parkinson’s Disease
Natalie C. Komadina, Zoe Terpening, Yue Huang, Glenda M. Halliday, Sharon L. Naismith, Simon J.G. Lewis
Dementia and Geriatric Cognitive Disorders.2011; 31(5): 349. CrossRef
Characterizing mild cognitive impairment in Parkinson's disease
John C. Dalrymple‐Alford, Leslie Livingston, Michael R. MacAskill, Charlotte Graham, Tracy R. Melzer, Richard J. Porter, Richard Watts, Tim J. Anderson
Movement Disorders.2011; 26(4): 629. CrossRef

First
Prev
Page of 1
Next
Last

Search